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ABSTRACT 
Two distinct pathways of complement activation were 
identified in turkey serum. The first pathway, indicated by 
the lysis of sheep red blood cells sensitized with antibody 
(SSRBC) was inhibited by ethylenediamine tetraacetic acid 
(EDTA), ethylene glycol-bis-Paminoethyl ether-N,N,N',N'-
tetraacetic acid (EGTA) and carrageenan. In contrast, lysis 
of horse red blood cells (HRBC) was antibody-independent and 
was inhibited only by EDTA. Hence, the hemolytic activity 
against SSRBC and HRBC represent the classical and 
alternative complement pathways of turkeys, respectively. 
Treatment of turkey serum with zyrnosan or inulin caused 
depletion of hemolytic activity against both SSRBC and HRBC, 
suggesting the presence of a common complement pathway in 
turkeys. 
The third component of complement was identified and 
isolated from turkey plasma. Turkey C3 consisted of two 
peptide chains, a larger C3a ch~in (120,000 daltons) joined 
by disulfide bonds to a smaller C3~ chain (75,000 daltons). 
Using crossed-immunoelectrophoresis, turkey C3 was found to 
have a distinctive mobility (movement toward the anode) in 
complement-activated serum. A rabbit antiserum produced 
against turkey C3 caused agglutination of sheep red blood 
cells sensitized with antibody and complement, but did not 
cause agglutination of sheep red blood cells sensitized with 
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only antibody. Therefore, the isolated protein was a 
complement component. Based on structural and immunological 
analysis, and comparison to characteristics of human C3, the 
isolated protein was confirmed as turkey C3. 
Characterization of turkey complement and development of 
hemolytic assays facilitated analysis of the role of turkey 
complement in Escherichia coli infections of turkeys. 
Resistance to the bactericidal effects of serum mediated by 
complement was a characteristic of virulent E. coli isolated 
from turkeys. However, five E. coli strains were found to be 
serum-resistant/avirulent, suggesting that other factors are 
also required for virulence. Killing of some E. coli strains 
by turkey serum was mediated by activation of the alternative 
complement pathway, whereas activation of the antibody-
dependent classical pathway was required for killing of other 
E. coli strains. Hence, the complement system of turkeys was 
found to have a significant role in E. coli infections of 
turkeys in the absence and presence of antibody. 
1 
GENERAL INTRODUCTION 
There are several defense mechanisms elicited in the 
host in response to infectious agents. some of the host 
responses are nonspecific, killing varied types of organisms, 
while others may be limited to organisms to which the 
individual has had previous exposure. The complement system, 
a group of at least 18 serum proteins is an example of a 
nonspecific host defense mechanism, and it is considered to 
be a first line of defense. complement-mediated killing of 
organisms may occur through activation of the classical or 
alternative complement pathways. The classical pathway 
usually requires specific antibody for activation. Therefore 
it can have a significant role in immune individuals, but 
little if any effect in early infection. In contrast, the 
alternative pathway does not require specific antibody and is 
activated by direct binding of the third component of 
complement to the surface of an organism. The alternative 
complement pathway is an important element of natural 
resistance to many infectious agents. 
Activation of complement is synonymous with proteolytic 
cleavage of the various complement proteins. These proteins 
interact sequentially and result in the deposition of a 
membrane attack complex on the surface of an organism. 
Stable insertion of this complex into the cell membrane of an 
organism causes irreversible membrane damage and cell death. 
2 
In addition to the formation of a lytic complex, complement 
activation leads to the release of several protein fragments 
with important biological functions. ·Fragments of these 
complement proteins function in immune adherence, chemotaxis, 
opsonization, and mediation of acute inflammation. Hence, 
activation of complement by an invasive organism can have a 
marked effect on the outcome of infection. 
study of the role of avian complement in disease 
pathogenesis has been limited because very few components of 
complement have been purified from avian species. 
Manipulation of the avian complement system using known 
activators of mammalian complement has identified a role for 
complement in several viral infections. Although complement 
is assumed to have an important role in bacterial infections 
of poultry, very little research has emphasized this area. 
Escherichia coli is a commonly isolated bacterial 
pathogen of broiler chickens and turkeys. Severe economic 
losses in poultry flocks infected with E. coli result from 
high mortality and carcass condemnations. Disease caused by 
E. coli is often characterized as subacute fibrinopurulent 
airsacculitis or acute colisepticemia. The latter form of 
the disease is often fatal. In order for E. coli to cause 
septicemia, bacteria must survive and multiply in the 
bloodstream of the host. Therefore, virulent E. coli must 
resist the bactericidal effects of serum mediated by 
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complement. An understanding of the virulence mechanisms of 
E. coli may be facilitated by studying the role of complement 
in defense against E. coli. 
The objectives of this research were to: 1. characterize 
the complement activity of turkeys; 2. isolate and 
characterize the third component of turkey complement; and, 
3. clarify the role of complement in defense against E. coli 
infections in turkeys. 
Explanation of Thesis Format 
This thesis is prepared in the alternate format. A 
general introduction and literature review precede four 
manuscripts dealing with turkey complement and the 
interaction of complement with Escherichia coli isolated from 
turkeys. The final manuscript is followed by a general 
discussion section and literature cited in the literature 
review and final discussion. 
The four sections of this thesis represent the 
manuscripts which have already or will be submitted for 
publication in scientific journals under the authorship of 
Marlene G. Ellis, Susan J. Lamont and Lawrence H. Arp. 
Marlene G. Ellis was the principal investigator of each 
study. Each section is prepared according to the format for 
the journal, Infection and Immunity. 
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LITERATURE REVIEW 
An overview of the complement system, its functions and 
the specific mechanisms of regulation will be presented to 
familiarize the reader with the primary focus of this thesis. 
Research in the area of complement is extensive, and the 
reader is ref erred to several good reviews of the complement 
system and its activation (22, 86, 87, 89) .. Following this 
introduction to the complement system, a detailed description 
of avian complement will be presented. The final section in 
this literature review discusses the interaction of 
complement with bacteria. Several reviews of complement and 
its interaction with bacteria are available to the reader 
(13, 15, 30, 48). 
The complement System 
The complement system consists of a group of at least 18 
serum proteins that actively participate in the nonspecific 
mechanisms of host defense against bacteria, viruses and 
parasites (89). Complement mediates its effects through 
direct interaction with pathogens (75), or by indirect 
interaction via specific immunoglobulin (antibody) (14, 33). 
Therefore, the complement system can have an important role 
in both immune and nonimmune individuals .. Upon activation, 
complement components react in a specific sequence resulting 
in the formation of enzyme complexes, which cleave the next 
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complement component in the sequence. In this sense, 
complement activation refers to proteolytic cleavage of the 
respective complement components. The final result of this 
cascade of proteins is the deposition of a membrane attack 
complex onto the target cell surface (86, 98). Insertion of 
this complex into the cell membrane creates water- and ion-
permeable channels culminating in osmotic lysis of the target 
cell (71). Hence, one function of complement may be the 
direct killing of infectious agents by disrupting the 
selective permeability of the cell membrane. In addition, 
several peptide fragments are generated during complement 
activation which are known to influence host defense 
mechanisms. A discussion of their function in defense 
against infectious agents will be developed later in this 
review. 
Complement is now recognized as a multifunctional, self-
assembling system that is important in humeral defense, as 
well as in stimulation of cellular defense mechanisms (85) . 
A unique feature of complement which facilitated its 
identification is that it is heat labile, being inactivated 
by heating serum to 56°c for 30 minutes. Much of the 
information on complement derives from studies of the human 
or guinea pig complement systems. Purification of isolated 
complement components has facilitated studies on the 
complement activation sequence and the specific mechanisms of 
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regulation. The molecular weight and concentration in the 
serum of each of the human complement components is presented 
in Table l. 
Two pathways of complement activation are known to exist 
in mammals, specifically the classical (22) and alternative 
(87) pathways. These pathways converge at the cleavage of 
the third component of complement (C3) and continue with a 
common terminal pathway involved in the formation of the 
membrane attack complex (86, 98). The interaction of these 
pathways is illustrated in Figure l. The events of the 
classical and alternative pathways described in the following 
sections are the result of cell-surface associated complement 
activation. Therefore, two or more components forming a 
multimolecular complex are assumed to be in close proximity 
on the cell surface. 
The Classical Pathway 
The classical pathway, so named because it was the first 
to be identified and characterized, was originally observed 
through its bacteriolytic and bactericidal effects on 
specific antibody-bacterial complexes (72). Therefore, this 
activation pathway is important in immune individuals. study 
of the reaction mechanism of the classical pathway was 
facilitated by the observation that complement could also 
lyse erythrocytes sensitized with specific antibody (ll). 
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Table 1. Molecular weight and concentration of complement 
components in human serum (73) 
Serum 
Component Mel. wt. concentration Chain no. x mol. wt 
(ug/ml) 
Classical Pathway: 
Clq 410,000 150-180 6 x 24,000 
6 x 23,000 
6 x 22,000 
Clr 85,000 50 1 x 85,000 
Cls 85,000 100 1 x 85,000 
C4 210,000 400-450 1 x 90,000 
1 x 78,000 
1 x 33,000 
C2 110,000 30 1 x 110,000 
Alternative pathway: 
B 93,000 200-225 1 x 93,000 
I;J 25,000 1.5 1 x 25,000 
p 220,000 10-25 4 x 56,000 
Common Pathway: 
CJ 195,000 1200-1300 1 x 110,000 
1 x 85,000 
C5 205,000 80 1 x 120,000 
1 x 85,000 
C6 128,000 75 1 x 128,000 
C7 121,000 55 1 x 121,000 
ca 155,000 80 1 x 77,000 
1 x 63,000 
1 x 14,000 
C9 79,000 200 1 x 79,000 
Figure 1. The activation sequence of the mammalian 
complement system 
9. 
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Hence, because erythrocytes possess a single membrane and are 
less complex than bacteria, simplified systems were developed 
using sensitized sheep red blood cells to elucidate the 
mechanisms of the classical pathway, as well as the terminal 
complement pathway (4, 11, 79). 
The initial step in the activation sequence of the 
classical pathway is the non-covalent binding of the first 
complement component (Cl) to an antigenic surface via 
specific antibody (99), or in some cases, by direct non-
immunological binding of Cl to complex molecules such as 
those listed in Table 2. The first component occurs 
naturally in serum as a complex of three different subunits, 
Clq, Clr and Cls having the molecular formula, 
Clq(Clr) 2 (Cls) 2 (22). This complex is calcium-dependent with 
the Clq subunit binding three calcium ions and the 
(Clr) 2 (Cls) 2 complex held together by four calcium ions. 
Chelators of calcium ions such as ethylenediamine tetraacetic 
acid (EDTA) or ethylene glycol-bis-fiaminoethyl ether-
N, N, N', N' -tetraacetic acid (EGTA) dissociate Cl thus 
rendering the classical pathway inactive (78). Interaction 
of Cl with an activating surface occurs through the Clq 
subunit. Clq is a highly basic protein and therefore can 
interact noncovalently with many polyanionic substances as 
shown in Table 2. The Clq molecule is composed of six 
peripheral globular regions, each containing a binding site 
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Table 2. Substances that bind and activate the first 
component of complement (73) 
Bacteria: Carbohydrates: 
E. coli 
Klebsiella 
Salmonella 
Mycoplasma 
Ant venom polysaccharide 
certain di- and trisaccharides 
Dextran sulfate 
Retroviruses 
Parasites 
Schistosoma mansoni 
Trypanosoma brucei 
Proteins: 
p15E retroviral surface protein 
c-reactive protein complexes 
Myelin basic protein 
Immunoglobulins 
Miscellaneous: 
Monosodium urate crystals 
Mitochondrial membranes 
Certain cellular membranes 
Nitrophenylated molecules 
Polyanions: 
Heparin 
Polyvinyl sulfate 
Polyanethol sulfonate 
Polynucleotides 
Carrageenan 
Lipids: 
Lipid A 
Lipoteichoic acid 
for immunoglobulin (89). Therefore, one Clq molecule can 
have up to six binding sites for immunoglobulin molecules, as 
well as other types of activating molecules. Only certain 
classes and subclasses of immunoglobulins are important in 
the binding of Clq and hence, classical pathway activation. 
In humans, IgM is a potent activator of the classical 
pathway, whereas IgG is less effective (89). Only one IgM 
molecule is needed to activate the classical pathway, whereas 
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at least two IgG molecules in close proximity are required 
for binding and activation of Cl. The human IgG subclasses, 
IgG
3
, IgG
1 
and IgG2 , listed in decreasing order of Clq 
binding activity, are efficient complement activators, 
whereas IgG4 binds complement poorly (22). The interaction 
of Clq with immunoglobulin occurs through the CH2 domain of 
IgG or the CH4 domain of IgM (22). Recent evidence suggests 
that the CH3 domain of IgM may also be important for the 
binding of Clq (109). 
Upon binding to the activating surface, a conformational 
change occurs in Clq. By some unknown mechanism, this 
conformational change leads to the activation of one of the 
attached Clr subunits (73) . This activated Clr subunit 
cleaves the polypeptide chain of the Clr subunit, and exposes 
its catalytic site (autocatalytic activation) (62). Both Clr 
subunits have enzymatic activity for the two Cls molecules 
associated with the complex. After cleavage by Clr, a 
catalytic site with enzymatic activity for the second (C2) 
and fourth (C4) components of complement is exposed on Cls. 
Activated Cls initially cleaves C4 into two fragments. The 
larger fragment, C4b binds covalently to the activating 
surface (89). The C2 component associates with surface-bound 
C4b in the presence of magnesium ions, and is subsequently 
cleaved by activated Cls (73). The complex, C4b2a forms an 
enzyme termed C3 convertase of the classical complement 
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pathway. The C3 convertase cleaves the third component of 
complement, yielding a larger fragment, C3b which interacts 
covalently with the activating surface (68). Interaction of 
C3b with the C4b2a complex results in the formation of a CS· 
convertase (C4b2a3b), and initiates the terminal pathway of 
complement activation (89). 
The Alternative Pathway 
Activation of the alternative complement pathway was 
first observed and proposed by Pillemer and colleagues in 
1954 (94). It was observed that zymosan, a crude preparation 
of yeast cell walls could activate complement without the 
consumption of the initial components (Cl, C2, and C4) of the 
classical pathway (95). complement activation by zymosan 
proceeded in the absence of specific antibody, and it was 
suggested that an alternative pathway may be important in 
resistance to infections in non-immune individuals. Since 
this early discovery, several substances have been reported 
to activate the alternative complement pathway in the absence 
of antibody, and some of them are listed in Table 3. 
The covalent binding of C3b to the activating surface is 
an essential requirement for activation of the alternative 
pathway (87, 89). However, the mechanism of formation of 
the initial C3b is unclear. It was proposed by Lachmann that 
a "C3 tickover" occurs naturally in serum (64). He suggested 
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Table 3. Substances that activate the alternative complement 
pathway 
substance References 
Polysaccharides: 
Yeast ( zymosan) 
Bacterial lipopolysaccharide 
Inulin 
Immunoglobulins: 
guinea pig IgG1 ; aggregated 
human IgG ; IgA; IgE; 
F(ab 1 ) 2 f!agments of IgG 
Cobra venom factor 
Heterologous erythrocytes 
Dextran sulfate 
95, 107 
51, 84 
73, 91 
18, 33, 89, 106 
21 
88, 91 
73 
that C3 interacts with water, forming a C3b-like molecule 
which can react with additional components (factors B and D) 
of the alternative complement pathway. A weak C3 convertase, 
C3(H20)Bb is produced which is able to cleave C3, yielding 
the initial C3b molecules. More recent evidence suggests 
that this is true, and that C3 can spontaneously interact 
with water, forming a C3b-like molecule (29). Under normal 
conditions, the spontaneously formed C3b is rapidly 
inactivated (67, 105). Substances such as zymosan, or 
certain strains of bacteria present in the serum can bind C3b 
and hence may activate the alternative complement pathway 
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(24, 84). Whether a substance is able to activate the 
alternative complement pathway depends on the stability of 
C3b and its susceptibility to inactivation by factor H and 
C3b-inactivator (see Regulation of the Complement System, 
page 22). It should be noted that the classical and 
alternative pathways are not mutually exclusive. Molecules 
of C3b formed via the classical pathway may initiate the 
alternative pathway upon binding to the activating surface. 
Once C3b is surface-bound, it interacts noncovalently 
with factor B. Factor D, a serine protease present in its 
active form in serum specifically cleaves factor B into two 
fragments. The larger fragment, Bb remains associated with 
C3b to yield the C3 convertase, C3bBb. This CJ convertase is 
stabilized by the serum protein, properdin (P) (81). The 
C3bBbP complex is able to cleave C3 and generate additional 
molecules of C3b. An amplification loop occurs in which 
newly formed C3b molecules interact with factors B, D, and P 
to form additional CJ convertases (87). This leads to the 
deposition of large amounts of C3b on the activating surface. 
Interaction of two or three molecules of C3b with one 
molecule of Bb in the presence of properdin forms the cs 
convertase, (C3b) 2BbP thus initiating the terminal complement 
pathway (89). 
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The Terminal Pathway 
The classical and alternative complement pathways 
converge with the cleavage of the third component of 
complement, as shown in Figure l. After C3 is cleaved, the 
larger fragment, C3b interacts with the C3 convertase to form 
the respective CS convertase of either the classical 
(C4b2a3b) or alternative (C3bBbPC3b) pathways. Cleavage of 
cs produces a larger fragment, CSb which initiates formation 
of the lytic complex of complement (86, 98). The remainder 
of the complement pathway does not involve enzymatic 
cleavages, but rather a self-assembly of the final complement 
components. The CSb fragment generated by the cs convertase 
contains a labile binding site, and must interact with the 
next component, CG, within milliseconds (6) . Interaction of 
CSb with CG results in a stable bimolecular complex that is 
loosely associated with surface-bound C3b (86) . Upon binding 
of C7, conformational changes occur, exposing hydrophobic 
binding sites on the CSb67 complex (3). Expression of these 
hydrophobic domains on the surface of the CSb67 complex 
allows it to partially insert into the phospholipid bilayer 
of the target membrane (80). At this stage, very little 
damage occurs to the target membrane, and the CSb67 complex 
is relatively stable in the membrane. Binding of ca to the 
CSb67 complex creates a small membrane pore that is 
sufficient to lyse erythrocytes, but not nucleated cells or 
17 
bacteria (86). The C5b678 complex serves to concentrate C9 
and facilitate its polymerization on the target cell membrane 
(128). The poly-C9 forms the hydrophilic channel of the 
membrane attack complex which is responsible for lysis of 
nucleated cells and bacteria (54, 86). The interaction of 
these final components (C5b-9) forms the membrane attack 
complex of complement which is responsible for cell lysis. 
The Membrane Attack complex and Mechanisms of cytolysis 
The actual molecular formula and weight of the membrane 
attack complex is not known because the C5b-9 complex has a 
tendency to aggregate after detergent solubilization (126). 
Current evidence indicates that the membrane attack complex 
may be composed of a dimer of C5b-8 plus a polymer of twelve 
to eighteen C9 molecules (8, 127). The approximate molecular 
weight of this (C5b-8) 2C9 12_18 complex is estimated to be 
greater than 1,000,000 daltons (6). 
Ultrastructural analysis of the complement lesions on 
erythrocyte membranes shows electron-dense "holes" surrounded 
by ring-like structures (126). This observation was 
described by Borsos and colleagues and referred to as the 
"doughnut hypothesis" (11). Further analysis by Mayer 
suggested that the ring structure may be a transmembrane 
channel formed by the C5b-9 complex (79). The complete 
structure of the membrane attack complex in the target 
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membrane is now described as a short, hollow cylinder rimmed 
by an annulus exterior to the membrane (5, 126). The 
external and internal diameters of the ring-like structure 
are 20 nm and 10 nm, respectively (126). The length of the 
cylindrical structure of the membrane attack complex is 
approximately 15 nm (126). Although the size of the membrane 
attack complex is quite uniform, heterogeneity is observed in 
the functional pore size (100). The heterogeneity in 
functional pore size is attributed to either differences in 
the number of C9 molecules associated with the complex, or 
"fusion" of individual monomers of C5b-9 (101, 111). 
The exact depth which the membrane attack complex 
inserts into the lipid bilayer of the membrane is uncertain. 
Studies with freeze-etch electron microscopy suggest 
insertion of the membrane attack complex to a depth of 4 to 
5 nm (4, 5). Therefore, the inserted protein complex would 
span the external lipid monolayer and extend at least 
partially into the internal lipid monolayer of the target 
erythrocyte membrane. The remaining portion of the cylinder 
and annulus extend from the membrane to the extracellular 
environment (5) . Two models have been proposed to explain 
the mechanisms of cytolysis by the membrane attack complex. 
The "mixed micelle model" described by Esser et al. suggests 
that the membrane attack complex has membranodisruptive 
characteristics (23). Insertion of the membrane attack 
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complex into the target membrane would cause disruption of 
the lipid bilayer and thus, result in membrane leakiness. In 
this case, the complement lesions would be poorly-defined in 
size, unstable in the membrane and perhaps, membrane 
disassembly would be observed (7). The alternative "channel 
model" proposed by Mayer suggests that the membrane attack 
complex would assume properties of an integral membrane 
protein and form a stable hydrophilic transmembrane pore 
through which ions and small molecules may pass 
bidirectionally (79, 80). Because of the high density of 
solute within the cell, water and electrolytes move into the 
cell via the complement pore causing cell lysis. The latter 
model is now generally accepted. However, the actual 
mechanisms of cytolysis probably involve a combination of the 
two models (7). Diffusion of water and small molecules into, 
or from the cell may occur both through the hydrophilic 
protein pore and along the boundary lipid. 
Complement Fragments and their Function 
As described previously, complement activation refers to 
the proteolytic cleavage of the respective complement 
components into two fragments. The larger fragments (e.g. Bb, 
C3b, C4b, CSb, etc.) usually continue to function in the 
assembly of the membrane attack complex, while the smaller 
fragments (e.g. Ba, C3a, C4a, csa, etc.) are released into the 
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tissue sites of complement activation (73). These smaller 
fragments of complement are responsible for several important 
biological functions during host defense against invasive 
organisms (7, 89). Some of the complement fragments and 
their known functions are summarized in Table 4. 
The overall role of the complement system is the 
destruction and removal of infectious agents from host 
tissues (15, 30). The complement system effects its action 
through the formation of the membrane attack complex and 
release of activated complement fragments. The membrane 
attack complex has a significant role in the killing of 
certain strains of gram-negative bacteria and virus-infected 
cells (66, 90, 121). In contrast, the membrane attack 
complex has very little influence on gram-positive bacteria, 
and some strains of gram-negative bacteria (13, 52, 53). The 
complement fragments released into the surrounding tissues 
have a more significant effect on these complement-resistant 
organisms. 
In general, some of the complement fragments are 
chemotactic for phagocytic cells, some facilitate 
phagocytosis (opsonins) and others stimulate an inflammatory 
response. Opsonization of organisms by fragments of 
complement can be an important host defense mechanism (48). 
Cell surface receptors for Clq, C4b, C3b (C3bi, C3d) and C5b 
have been found on phagocytic cells (22, 73, 87). For 
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Table 4. Biological functions of activated complement 
components (73) 
Complement Functions 
component 
C2a Kinin-like activity; increase of vascular 
permeability and contraction of smooth muscle 
C3a,C4a,C5a 
C5a,C5b67,Ba 
C3b,C4b 
Anaphylatoxic peptides bind to receptors on 
granulocytes, macrophages, mast cells, and 
thrombocytes; release of vasoactive amines; 
enhanced vascular permeability; contraction 
of smooth muscle; induced release of 
lysosomal enzymes 
Chemotaxis; induction of migration of 
leukocytes into an area of complement 
activation; granulocyte aggregation; 
activation of intracellular process, such as 
release of oxygen metabolites and SRS-A 
Immune adherence and opsonization; bridging 
between a complex or target cell bearing C3b 
or C4b and the responding cell having a 
receptor for C3b or C4b: phagocytic cells, 
macrophages, monocytes, polymorphonuclear 
leukocytes, B lymphocytes, primate 
erythrocytes, platelets 
example, cells of the mononuclear phagocytic system have 
receptors for C3b, and hence, play an important role in the 
clearance of opsonized organisms from the bloodstream (13, 
48). Hence, the conjoint action of the complement system and 
the phagocytic cells has a significant influence on survival 
of infectious organisms in host tissues. 
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Regulation of the Complement system 
The effects of complement are very localized and limited 
to the site of complement activation (85). Rapid 
inactivation of complement fragments by various serum 
regulators is essential for preventing lysis of innocent 
bystander cells, a process known as "reactive lysis" 
(65, 125). Several steps in the complement activation 
sequence are subject to regulation. Three levels of 
regulatory mechanisms coexist. 
Firstly, certain serum proteins have been identified 
that react specifically with activated complement components 
causing their inactivation, as shown in Table 5. Most of 
these regulators act either by cleaving the activated 
complement protein or by dissociating complexes of complement 
proteins. In each case, there is a loss in complement 
activity. 
A second regulatory mechanism exists for certain 
complement. proteins. several of the activated complement 
fragments expose binding sites, which interact with the next 
complement component in the sequence, or with cell surfaces. 
Many of these binding sites on the activated molecules are 
metastable, and usually have only milliseconds to react with 
a receptor molecule (85). This has been identified to occur 
with the reactive groups in C4b, C3b, and C5b (99, 33, 98). 
The unavailability of receptive surfaces for the activated 
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Table 5. Regulators of complement activity (89, 99) 
Regulator Mechanism of Action 
Cl Inhibitor 
C3b-Inactivator 
(Factor I) 
Factor H 
C4b-binding protein 
s Protein 
Anaphylatoxin 
Inactivator 
-Dissociates Clr and Cls from 
Clq. Thereby, indirectly inhibits 
activation of Cls and reduces the 
rate of cleavage of C4 and C2. 
-Inhibitor of other serum proteins 
(plasmin, kallikrein, Hageman 
factor). 
-Cleaves the alpha chain of 
C3b, and in the presence of 
unidentified serine proteases 
forms C3c and C3d. A loss in all 
opsonic, immune adherence, and 
C5 acceptor activities occurs 
with C3b inactivation. 
-Inactivates C4b by a similar 
mechanism to that of C3b. 
-Cofactor; binds to C3b and 
facilitates inactivation of C3b 
by Factor I. Binding of factor 
H is essential for C3b 
inactivation. 
-Cofactor; binds to C4b and 
accelerates inactivation of C4b 
by Factor I. 
-Binds to hydrophobic regions of 
the C5b67 complex, and prevents 
its uptake by cell surfaces of 
bystander cells. 
-Removes the c-terminal arginine 
residue from C3a and C5a, which 
inactivates the anaphylatoxic 
activity. 
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complement fragments leads to hydrolysis of these fragments, 
and hence, their inactivation. 
Thirdly, host cell surface structures are now recognized 
as being important in the regulation of complement activity. 
A common constituent on host cell surfaces is sialic acid, 
and evidence indicates that this molecule may have an 
important role in regulation of C3b deposition by the 
alternative complement pathway (25, 57). The classical 
example of this phenomenon is that of sheep red blood cells, 
which do not activate the alternative pathway. Removal of 
the sialic acid by treatment with trypsin renders the sheep 
red blood cells potent activators of the alternative pathway 
(25). Sialic acid is suggested to increase the affinity of 
factor H for C3b, and hence, make C3b more susceptible to 
inactivation by the C3b-inactivator (57). Therefore, absence 
of sialic acid on target cell surfaces may be required for 
activation of the alternative pathway. This is exemplified 
by zymosan and rabbit erythrocytes, which lack sialic acid on 
their surfaces and are potent activators of the human 
alternative pathway (88, 96, 107). However, other mechanisms 
of regulation must be in effect as the rabbit alternative 
pathway is not activated by homologous red blood cells. 
Another molecule suggested to be important in complement 
regulation is the C3b-receptor (CR-1) found on various host 
cells. This CR-1 receptor modifies C3b and C4b by some 
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unknown mechanism, and makes them susceptible to cleavage by 
C3b-inactivator (58, 82). The presence of the CR-1 receptor 
on host cells may be important in preventing lysis of 
homologous cells under normal conditions. For example, when 
C3b is spontaneously formed, its binding to homologous cells 
does not result in activation of the alternative pathway. 
The Third component (C3) of Complement 
The third component of complement plays a key role in 
the complement activation sequence. Both the classical and 
alternative complement pathways converge with the cleavage of 
C3 (73, 89). The activated fragments of C3 include an 
anaphylatoxin (C3a) and a surface-bound receptor (C3b) (17, 
33, 63). The membrane-associated C3b has important functions 
in opsonization, immune adherence, and formation of the C5 
convertase for final assembly of the membrane attack complex 
(48, 87, 130). Hence, because C3 is multifunctional it is a 
good candidate for analysis during disease pathogenesis. The 
importance of C3 is shown by the observation that its 
deficiency leads to severe recurrent bacterial infections 
( 45) . 
The third component of complement is the most abundant 
in human serum (approximately 1.2-1.3 mg/ml) (73). Isolation 
and characterization of C3 has been reported for several 
species, including human, rabbit, chicken and quail 
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(38, 41, 56, 59). Human C3 is characterized as a 
glycoprotein (195,000 mol. wt.) composed of a larger C3a 
chain (127,000 mol. wt.) joined by a disulfide bridge to a 
smaller C3~ chain (75,000 mol. wt.) (38). The C3 
convertases of the classical and alternative pathways 
activate C3 by cleaving the a chain, and releasing C3a 
(9,000 mol. wt.) (68). Cleavage of C3 exposes a reactive 
carbonyl group in the C3b fragment, which binds covalently 
(amide or ester linkage) to proteins or polysaccharides 
(18, 68, 93). one particular interaction of C3b is that with 
the immunoglobulin, IgG. The C3b-IgG complex is more 
efficient than IgG in sensitizing E. coli for complement-
mediated killing, as will be discussed later (47). 
The reactive group of C3b is believed to originate from 
an internal thiolester bond in C3 (46, 124). A similar group 
has been identified in C4 and a2-macroglobulin (110). This 
reactive thiolester bond is sensitive to amines (e.g. 
hydroxylamine, methylamine), ammonium salts, and denaturing 
conditions (extremes in temperature, pH, and reducing 
conditions with mercaptoethanol) (68, 110, 116). sensitivity 
to the nitrogen nucleophiles and appearance of a free thiol 
group after treatment with the nucleophiles provides some 
evidence that the reactive group in C3 is a thiolester bond 
(116, 124). It is suggested that this reactive thiolester is 
associated with the covalent binding mechanism of C3, and 
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therefore has an important role in the function of C3 (68). 
Inactivation of the thiolester bond by amines, etc., results 
in a loss of C3 activity (68, 124). Endogenous substances 
such as ammonia may have an important role in regulating this 
particular complement protein (42). 
The Avian Complement System 
Unlike the mammalian and human complement systems, 
relatively little is known about the avian complement system 
and its role in infection. Much of this lack of knowledge is 
due to the unavailability of purified complement proteins 
from avian species. Presently, most of the assays used in 
the study of avian complement analyze functional activity 
(e.g. lysis of erythrocytes or of virus-infected cells), and 
therefore do not identify functions of individual complement 
proteins (60, 135). Progress in the isolation of avian 
complement proteins has been made, as shown in Table 6 and 
the future availability of these individual proteins will 
facilitate characterization of the avian complement system 
and its role in host defense. 
The chicken complement system is the most widely studied 
system in avian species, followed by the turkey and quail 
systems. An initial feature of chicken and turkey complement 
to be described was their incompatibility with mammalian 
antibody (102). The incompatibility has been attributed to 
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Table 6. Complement proteins isolated from avian species 
species 
chicken 
quail 
complement protein 
Clq 
C4 
C3 
B 
C3 
reference 
134 
69 
59 
61 
56 
evolutionary differences between mammalian and avian species. 
Researchers have acknowledged this finding, and suggest that 
caution should be taken when applying assays which are used 
for the study of mammalian complement to the study of avian 
complement (59, 60). 
Evaluation of the hemolytic activity of chicken or 
turkey complement for sheep red blood cells sensitized with 
homologous antibody has indicated several characteristics. 
Firstly, hemolytic complement activity of chicken serum is 
much lower than that of several mammalian species including 
guinea pig, cat, dog and rabbit (35). A second distinct 
feature of chicken complement is its ability to cause 
hemolysis at low ionic strengths, a condition which severely 
limits the activity of mammalian complement (32). Thirdly, 
the functional complement activity of chicken and turkey sera 
increases with age, reaching maximal levels at approximately 
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six weeks of age (112). The hemolytic titers for chickens 
and turkeys at this age are 1:33 and 1:25, respectively. 
several studies have presented evidence suggesting the 
presence of an alternative pathway in avian species. Lysis 
of horse and rat erythrocytes is indicative of alternative 
pathway activity in chickens (60, 91). A role for the 
alternative complement pathway is well-established in some 
viral infections of poultry. The cytolytic activity of quail 
serum against Rous-sarcoma virus-infected cells and of 
chicken serum against fowlpox virus-infected cells is 
attributed to activation of the alternative complement 
pathway (90, 135). In vivo studies with fowlpox virus showed 
that decomplementation of chickens using cobra venom factor 
resulted in an enhancement of virus growth and dissemination 
of the virus throughout the host (92). In addition, it was 
noted that infiltration of polymorphonuclear cells, 
macrophages or lymphocytes to the site of viral infection was 
reduced in the cobra venom factor-treated chickens. These 
observations suggest that not only is complement activation 
important in the lysis of virus-infected cells, but may also 
be necessary for stimulation of cellular functions. 
There has been some controversy over the presence of a 
functional classical pathway in poultry species, and this may 
perhaps explain the incompatibility between avian and 
mammalian systems (59, 60). An antibody-dependent, calcium-
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dependent pathway is described in the chicken (91, 135). 
However, there is some hesitancy in defining it as the 
classical pathway. Although the initial component of the 
classical pathway (Clq) has been identified in chickens, it 
was suggested by one group that chicken C2 and C4 may be non-
existant (60). The basis for this hypothesis was not clearly 
indicated. Although there is no published data available, 
the fourth component (C4) of chicken complement was isolated 
and characterized by w. H. Lee (69). At this point, the 
requirement for purified avian complement proteins is 
emphasized. Availability of these proteins will facilitate 
analysis of the avian complement system, and provide direct 
evidence for an avian classical complement pathway. 
The complement system and Defense Against Bacteria 
The precise role for complement in defense against 
bacteria depends on several factors related to the type of 
organism, its cell surface composition and other virulence 
factors (48). The effects of complement on gram-negative 
bacteria are different from those described for gram-positive 
bacteria (13, 121). The difference is attributed to the 
bacterial cell wall structure. Gram-negative bacteria have a 
more complex cell wall structure than gram-positive bacteria. 
The cell envelope of gram-negative bacteria consists of four 
layers: the cytoplasmic membrane; the peptidoglycan layer; 
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the periplasmic space; and the outer membrane (47). In 
contrast, the gram-positive bacterial cell wall lacks the 
outer membrane, and has a much thicker peptidoglycan layer 
(13). Additional capsular polysaccharide may be present on 
the surface of both gram-negative and gram-positive bacteria. 
Because there are differences between gram-negative and gram-
positive bacteria and their interaction with complement, they 
will be addressed separately, with emphasis on gram-negative 
bacteria. 
Interaction of Complement with Gram-Negative Bacteria 
The outer membrane of gram-negative bacteria and its 
surface constituents are exposed to the microenvironment of 
the bacteria. The outer membrane is not composed of the 
normal phospholipid bilayer as seen with the cytoplasmic 
membrane, or with eucaryotic membranes (39). Instead, the 
inner monolayer contains primarily phospholipid and the outer 
monolayer contains lipopolysaccharide (LPS). The LPS is 
anchored in the outer membrane by hydrophobic binding to 
membrane proteins. Divalent cations, calcium and magnesium 
are suggested to be important in maintaining stable 
interactions between adjacent LPS molecules, and hence the 
integrity of the bacterial cell envelope (76). Chelation of 
these cations by EDTA or EGTA releases large amounts of LPS 
from the membrane (39, 70). For example, up to 67% of the 
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' total LPS in E. coli may be released by treatment with EDTA 
(39). With the release of LPS, the membrane becomes more 
permeable to various molecules, and susceptible to attack by 
colicins, antibiotics and complement (16, 39, 70). 
The LPS is unique to gram-negative bacteria. It is 
composed of three covalently-linked domains: the lipid A, the 
core polysaccharide and the o-polysaccharide side chain. The 
lipid A is the portion through which the LPS is anchored in 
the membrane. The lipid A has toxic properties, therefore, 
LPS is often referred to as endotoxin. The core 
polysaccharide is invariable among gram-negative bacteria, 
and consists of residues unique to procaryotes. The o-side 
chain is the outermost region of LPS, and consists of 
repeating units of oligosaccharides. It is the o-side chain 
which determines the serological specificity of an organism. 
The length of the 0-side chain varies from strain to strain, 
ranging from smooth variants with long, complete LPS 
molecules to rough variants which lack the o-side chain of 
LPS. 
In general, gram-negative bacteria are more susceptible 
to the bactericidal effects of complement than gram-positive 
bacteria (20). In the absence of antibody, complement may be 
activated by the classical (75, 104) or alternative (103, 
108) pathways upon interaction with gram-negative bacteria. 
The primary molecule responsible for non-immunological 
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activation of the complement system is LPS (27). The lipid A 
portion of LPS binds Clq and activates the classical pathway 
(75). Hence, rough bacterial strains which lack the o-
polysaccharide side chain may be efficient activators of the 
classical pathway. This antibody-independent activation of 
the classical pathway by some strains of gram-negative 
bacteria may require an additional undefined serum protein 
(19) • In contrast, the alternative pathway is usually 
activated by the o-polysaccharide side chain of LPS (84). 
Polysaccharides are well known acceptors of activated C3b, 
and it is suggested that the complex polysaccharides of 
bacterial LPS may serve as acceptors of the initial C3b 
molecules (18). Deposition of C3b on the o-side chain of LPS 
in a "protected site" from factor H and C3b-inactivator 
allows activation of the alternative complement pathway by 
certain strains of gram-negative bacteria. The length and 
composition of the o-side chain can influence the capacity of 
bacteria to activate complement (84). 
An additional cell surface structure of gram-negative 
bacteria which may interact with complement is the capsular 
polysaccharide. Because of its high charge and hydrophilic 
nature, the capsular polysaccharide does not activate 
complement efficiently (1, 129). In addition, certain 
polysaccharide capsules such as the Kl capsule of E. coli do 
not activate the alternative complement pathway (114). The 
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Kl capsule of E. coli is a homopolymer of sialic acid, a 
molecule involved in the inactivation of surface-bound C3b, 
as described earlier. 
Although some strains of bacteria are killed in the 
absence of antibody, many strains usually require the 
presence of specific antibody. For example, antibody 
markedly increased the rate of killing of Kl E. coli isolates 
(115). The bactericidal antibodies may be specific for o-
antigens, outer membrane proteins or capsular polysaccharides 
(15, 104). Antibody serves three functions in complement-
mediated defense against bacteria. Firstly, it may 
facilitate activation of the classical pathway. Many of the 
Kl E. coli strains require antibody for their killing by the 
classical pathway (115). Secondly, it may enhance C3b 
deposition by the alternative pathway (50, 51). The IgG-C3b 
complexes are more efficient in opsonization and killing of 
bacteria (37). The killing may be the result of C5b-9 
localization near membrane-bound IgG-C3b complexes (49). 
Thirdly, antibody may increase the bactericidal efficiency of 
the C5b-9 complex by localizing the complex near IgG-C3b 
complexes or stabilizing it in the outer membrane of bacteria 
(49, 50). 
The ability to survive the bactericidal effects of 
complement establishes the basis for serum-resistant and 
serum-sensitive gram-negative bacterial strains (118). The 
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mechanisms by which complement causes killing of certain 
bacterial strains are not understood. Complement-mediated 
killing of bacteria is quite different from the lysis of red 
blood cells. Gram-negative bacteria possess a more complex 
cell envelope, have the capacity to multiply rapidly and 
respond to environmental stressors (phenotypic variation), 
and are able to deviate energy sources for repair of damaged 
sites (121). Hence, it is understandable that more effective 
molecules of complement are needed for the killing of gram-
negative bacteria, in comparison to lysis of red blood cells. 
For example, it has been estimated that at least 800 to 1000 
C5b-9 complexes per colony-forming unit of E. coli are needed 
for killing by human serum (53). 
The events which occur after interaction of complement 
wi~h serum-sensitive bacterial strains are partially defined. 
Initially, there is a short lag phase in growth, followed by 
a rapid loss in viability by 80 minutes after treatment of 
bacteria with serum (119). Release of periplasmic proteins 
and phopholipids has been reported to occur during serum 
killing of bacteria (26, 108). The phospholipids are 
suggested to originate from the bacterial outer membrane or 
from the periplasm (108). However, loss of either material 
is not apparently related to bacterial killing (121). 
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Both bacterial-derived energy sources, and 
macromolecular biosynthesis (DNA, RNA, and protein) may be 
required for efficient killing of bacteria by complement 
(114, 119). The reasons for these requirements are unclear. 
It was suggested that serum-sensitive bacterial strains may 
translocate the C5b-9 complex from the outer membrane to the 
inner membrane by means of its own energy sources (119). 
However, more recent evidence suggests that this does not 
occur. Examination of the inner membrane from serum-
sensitive E. coli indicated that very few of the complement 
components of the membrane attack complex were deposited on 
it (120). This would suggest that the membrane attack 
complex of complement mediates its killing from the outer 
membrane of gram-negative bacteria. 
At the present time, the mechanism for complement 
killing is believed to be the result of perturbation of the 
inner membrane. Taylor and Kroll proposed that there is a 
transient contact of the inner membrane with the membrane 
attack complex (121). Several reports have suggested that 
this contact may occur at the bioadhesion zones where the 
outer and inner membranes are temporarily joined together 
(10, 121, 133). The function of these bioadhesion zones are 
not known. It has been suggested that they may have a role 
in transport of newly synthesized outer membrane proteins or 
LPS molecules from the inner membrane to the outer membrane 
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(76) . It may be that damage of the outer membrane by the 
membrane attack complex stimulates protein synthesis and cell 
repair, resulting in the formation of bioadhesion zones. 
This may allow interaction of the membrane attack complex 
with the inner membrane at times of cell repair. A 
disturbance of the inner membrane may cause a potassium 
efflux, membrane depolarization and hence, bacterial death 
(10). This is supported by the fact that disruption of the 
outer membrane is separable from disruption of the inner 
membrane (26) . An understanding of the biochemical and 
cellular events that occur during complement attack on 
bacteria may be necessary to elucidate the mechanisms of 
complement killing. 
Several bacterial strains have developed virulence 
factors to avoid the lethal attack of complement. These 
organisms are usually the cause of many types of disease 
(43, 113, 114). surface structures associated with 
complement resistance include the capsular polysaccharide 
(34, 43), smooth lipopolysaccharide (36, 97), and outer 
membrane proteins (83, 122). No one specific structure has 
been associated with complement resistance, and it appears 
that a combination of these virulence factors are needed for 
complete complement resistance (123). The mechanism for 
complement resistance centers on the interaction of the 
membrane attack complex with the bacterial outer membrane. 
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For example, stable insertion of the C5b-9 complex into the 
outer membranes of Escherichia coli and Salmonella minnesota 
is required for bacterial killing (52, 53). Release of the 
membrane attack complex from the outer membrane is associated 
with the serum-resistant strains of these organisms. In 
contrast, studies with gonococci indicate that both serum-
sensitive and serum-resistant strains have a stable 
interaction with the membrane attack complex (40, 55). It is 
suggested that serum-resistant gonococci may alter the 
orientation of the membrane attack complex in the outer 
membrane, or they may have different sites for attachment of 
the complex (15). Hence, it can be seen that the mechanisms 
for complement resistance are complex, depend on the 
bacterial species, and understanding them requires molecular 
analysis of the bacterial surface structures and their 
interaction with complement components. 
Interaction of complement with Gram-Positive Bacteria 
Several gram-positive bacteria, including strains of 
Streptococcus pneumoniae, and Staphylococcus aureus have been 
shown to activate either the classical or alternative 
complement pathways in the absence of specific antibody 
(13, 31, 131). The nature of the structures involved in 
complement activation are not well-defined. The lipoteichoic 
acid extending from the cytoplasmic membrane of gram-positive 
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bacteria may be important in direct binding of Clq and 
activation of the classical complement pathway (74). The 
peptidoglycan layer may activate the alternative complement 
pathway, but the extent of activation is limited (131). 
Gram-positive bacteria are generally considered to be 
serum-resistant (13). The ability to resist killing by 
complement is largely due to the thick peptidoglycan layer 
overlying the cytoplasmic membrane. The length of the 
membrane attack complex is approximately 15 nm (126). In 
comparison to a 160 nm thickness of the peptidoglycan layer 
of for example, streptococcus pneumoniae the effect of the 
membrane attack complex on gram-positive bacteria is minimal 
(13). Therefore, the role for complement in gram-positive 
bacterial infections is not one of cell lysis, but rather 
generation of opsonic complement fragments, such as C5b67 and 
C3b, as well as inflammatory stimulators, C5a and C3a (13). 
However, several pathogenic gram-positive bacteria, including 
streptococcus pneumoniae and Staphylococcus aureus are not 
markedly affected by these complement fragments. The reason 
for this complement resistance is that most of the opsonic 
fragments are deposited on the bacterial surface in areas 
where they are not exposed to phagocytic cells. For example, 
studies with Staphylococcus aureus indicated that C3b is 
deposited on the cell wall "hidden beneath" the bacterial 
capsule (132). It has been shown that anti-capsular antibody 
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redistributes the C3b to the capsule, and thus makes the C3b 
component a more efficient opsonin (14). In summary, 
complement in conjunction with antibody and the phagocytic 
system can provide an effective means of eliminating invasive 
gram~positive bacteria. 
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SECTION I. CHARACTERIZATION OF COMPLEMENT ACTIVITY IN 
TURKEYS: EVIDENCE FOR CLASSICAL AND ALTERNATIVE 
COMPLEMENT PATHWAYS 
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ABSTRACT 
The complement activity in turkey serum was examined by 
using activators or inhibitors of mammalian complement. 
Hemolytic test systems using sheep red blood cells sensitized 
with specific turkey antibody (SSRBC) and horse red blood 
cells (HRBC) were developed to measure complement activity of 
turkey sera treated with the various activators/inhibitors. 
Lysis of SSRBC was blocked by treatment with 6 mM EDTA, 
10 mM EGTA and carrageenan. In contrast, lysis of HRBC was 
blocked by 6 mM EDTA, but not by 10 mM EGTA or carrageenan. 
Addition of magnesium ions to EGTA-chelated serum facilitated 
the lysis of HRBC but not the lysis of SSRBC. Treatment of 
serum with zymosan at 1 mg/ml and inulin at 5 mg/ml depleted 
hemolytic activity against both SSRBC and HRBC, suggesting 
depletion of components common to both pathways. Differences 
in the hemolytic activities of sera against SSRBC and HRBC 
after treatment with the various complement activators and 
inhibitors suggest the presence of two complement pathways. 
The lysis of SSRBC is antibody-dependent and requires calcium 
and magnesium. This pathway is analogous to the classical 
complement pathway of mammals. The lysis of HRBC is 
antibody-independent and requires only magnesium. This 
pathway is analogous to the mammalian alternative complement 
pathway. Thus, both classical and alternative complement 
pathways were demonstrated in turkeys. 
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INTRODUCTION 
The complement system, a group of serum proteins, is 
involved in mediation of inflammation and nonspecific host 
defense against bacteria, parasites and viruses (4). Two 
pathways of complement activation are recognized in mammals, 
namely the classical and alternative pathways. The classical 
pathway is activated by specific antibody, or by certain 
polymeric substances such as heparin, protamine, carrageenan 
and lipid A of gram-negative bacteria (2). In contrast, the 
alternative pathway is not activated by specific antibody but 
by the covalent binding of the third component (CJ) to 
aggregated immunoglobulins or complex polysaccharides such as 
zymosan, inulin, and lipopolysaccharide of gram-negative 
bacteria (12). The classical and alternative pathways 
converge with the cleavage of CJ as the common pathway 
culminating in formation of a membrane attack complex. 
Insertion of this complex into biological membranes results 
in increased permeability and subsequent cell lysis (11) . 
Research on chicken complement strongly suggests the 
presence of both classical and alternative complement 
pathways analogous to the mammalian complement pathways. The 
lysis of sheep red blood cells sensitized with antibody is 
evidence of classical complement activity in chickens (13). 
Several viruses, as well as xenogenic red blood cells are 
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known to activate the chicken and quail alternative 
complement pathways (7, 13, 14, 18). Additional support for 
classical and alternative complement activities is shown by 
the specific isolation of complement components from both 
pathways (6, a, 9, 17). 
Basic information on the classical or alternative 
pathways of turkey complement is not available. The mean 
hemolytic titer of 6-week old turkeys was reported to be 1:25 
using the lysis of SSRBC as an indicator system (16). This 
titer gives a baseline measure for complement activity in 
turkeys. In this paper, we demonstrate the presence of 
classical and alternative complement pathways in turkeys. 
Also, concentrations of various complement activators that 
result in total depletion of one or both pathways of 
complement activity were determined. 
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MATERXALS AND METHODS 
Turkey serum. Blood was collected from normal adult 
turkeys (n=25) and allowed to clot at room temperature for 
1 hour and then at 4°c for 1 hour. Serum was harvested, 
pooled and divided into 10 ml aliquots. All serum was frozen 
at -7o0 c until required. 
Red Blood Cells. Sheep red blood cells (SRBC) and horse 
red blood cells (HRBC) were collected separately, and each 
was mixed with equal volumes of Alsever's solution. Red 
blood cells were washed twice in phosphate-buffered saline, 
pH 7.2, a thi.rd time in gelatin veronal buffer (GVB++) 
containing 0.15 mM calcium and 0.5 mM magnesium, pH 7.2 (5) 
and then resuspended in GVB++. Horse red blood cells were 
standardized to a concentration of 7 x 107 cells/ml for use 
in the hemolytic assay. Sheep red blood cells were 
sensitized with specific antibody by incubating a 1% SRBC 
suspension with an equal volume of 1:200 turkey anti-SRBC 
antibody at 37°c for 30 minutes. Sheep red blood cells 
sensitized with specific antibody (SSRBC) were then pelleted, 
resuspended in GVB++ and standardized to a concentration of 
1.4 x 108 cells/ml for use in the hemolytic assay. 
Hemolytic Complement Assays. The hemolytic activity of 
sera was determined using a round-bottom microtiter test 
plate system. Two-fold serial dilutions of test sera 
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(50 ul/well) were mixed with equal volumes of red blood cell 
suspensions (7 x 107 HRBC/ml or 1.4 x 108 SSRBC/ml). Plates 
were incubated at 37°c for 1 hour (SSRBC) or 2 hours (HRBC) 
as previously described (13). Microtiter test plates were 
then centrifuged to pellet unlysed cells. The dilution of 
serum causing an approximate 50% decrease in the red blood 
cell button was noted, and the hemolytic titer was then 
reported as the reciprocal of that dilution of serum, 
recorded as the log2 titer. All serum samples were tested in 
quadruplicate. 
Adsorption of Natural Antibody to HRBC from Turkey 
serum. In order to determine whether horse red blood cells 
were lysed by classical pathway or alternative pathway 
activation, anti-HRBC antibody was adsorbed from turkey 
serum, and then hemolytic activity against HRBC was 
determined. Turkey serum (1 ml) was mixed with 0.25 ml 
packed HRBC at 4°c for 15 minutes. Horse red blood cells 
were removed by centrifugation (1000 rpm, 10 minutes) and the 
adsorption was repeated a second time. The supernatant was 
collected after the second adsorption and tested for 
hemolytic activity against HRBC. 
Chelation of Divalent cations. Ethylenediamine 
tetraacetic acid (EDTA) and ethylene glycol-bis-µaminoethyl 
ether-N,N,N',N'-tetraacetic acid (EGTA) were prepared as 
0.1 M stock solutions. Turkey serum (1 ml) was chelated by 
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the addition of various concentrations of EDTA or EGTA. All 
samples were brought to a final volume of 1.1 ml using 
veronal-buffered saline without calcium and magnesium, and 
examined for hemolytic activity. 
Treatment of Turkey serum with Complement Activators. 
Various concentrations of zymosan (SIGMA, st. Louis, MO) and 
inulin (from Chicory root, SIGMA} were mixed with 1 ml of 
turkey serum. Samples were incubated for 30 minutes at 37°c, 
centrifuged (2000 rpm, 30 minutes, 4°c) and supernatants 
tested for hemolytic activity. Various concentrations of 
carrageenan (Type IV, Lambda, SIGMA} in 0.5 ml volumes were 
added to 0.5 ml turkey serum. Samples were mixed at 4°c for 
20 minutes and then centrifuged (2500 rpm, 20 minutes). 
supernatants were collected and tested for residual hemolytic 
activity. 
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RESULTS 
Adsorption of natural antibodies to HRBC from turkey 
serum had little effect (p > 0.05) on the hemolytic activity 
against HRBC. Mean hemolytic titers of nonadsorbed and 
adsorbed sera were 5.17 and 4.87, respectively. 
The influence of calcium and magnesium ions on the 
complement activity of turkey serum is shown in Figure 1. 
chelation of calcium and magnesium ions by EDTA at a final 
concentration of 6 mM blocked hemolytic activity against both 
SSRBC and HRBC. Chelation of calcium ions by EGTA at a final 
concentration of 10 mM blocked hemolytic activity against 
SSRBC, but did not block all hemolytic activity against HRBC. 
The hemolytic activity against HRBC decreased from 5.17 in 
normal serum to 2.96 in serum chelated with 10 mm EGTA. 
Addition of magnesium to serum treated with 10 mM EGTA 
restored hemolytic activity against HRBC to normal control 
values, as shown in Figure 2. Although hemolytic activity 
against SSRBC was increased by addition of magnesium, titers 
did not reach normal control values. Addition of magnesium 
to normal turkey serum is also shown in Figure 2, and the 
results indicate that hemolytic activity against either SSRBC 
or HRBC was not significantly affected by addition of 
magnesium (p > 0.05). 
Figure 1. 
Figure 2. 
Residual hemolytic activity against SSRBC or HRBC 
after chelation of calcium and magnesium ions 
from turkey serum by EDTA or EGTA. Data points 
represent the mean of four samples 
Influence of additional magnesium ions on 
hemolytic activity of normal turkey serum 
(control) and EGTA-chelated turkey serum. Data 
points represent the mean of four samples 
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Treatment of turkey serum with zymosan or inulin 
depleted hemolytic activity against both SSRBC and HRBC as 
shown in Figures 3 and 4, respectively. However, turkey 
complement was more sensitive to zymosan than to inulin. 
Whereas zymosan at only 1 mg/ml serum abolished hemolytic 
activity, at least 5 mg of inulin per milliliter of serum was 
required to abolish hemolytic activity. The effect of 
carrageenan treatment on turkey complement activity is shown 
in Figure 5. With increasing concentrations of carrageenan, 
hemolytic activity against SSRBC decreased significantly, 
whereas hemolytic activity against HRBC was not significantly 
affected (p > 0.05). The hemolytic titers of normal serum 
and carrageenan-treated serum (1.5 mg carrageenan/0.5 ml 
serum) against HRBC were 4.75 and 4.25, respectively. 
Figure 3. 
Figure 4. 
Depletion of hemolytic activity against SSRBC and 
HRBC by inulin treatment of turkey serum. Data 
points represent the mean of four samples 
Depletion of hemolytic activity against SSRBC and 
HRBC by zyrnosan treatment of turkey serum. Data 
points represent the mean of four samples 
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HRBC by carrageenan treatment of turkey serum .. Data 
points represent the mean of four samples 
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DISCUSSION 
The results of this study indicate that two complement 
pathways exist in turkeys. Lysis of HRBC by turkey 
complement is mediated through an antibody-independent 
pathway, as similarly described for chickens (13). A 
commonly used procedure to separate alternative pathway 
activation from classical pathway activation is differential 
chelation of calcium and magnesium ions by EDTA or EGTA. 
Both calcium and magnesium ions are chelated by EDTA, whereas 
only calcium ions are chelated efficiently by EGTA. Hence, 
chelation of serum by EGTA inhibits classical complement 
pathway activity but allows expression of alternative pathway 
activity (3). Treatment of turkey serum with EGTA did not 
inhibit all hemolytic activity against HRBC, suggesting 
that lysis of HRBC is via the alternative complement pathway. 
In contrast, lysis of SSRBC probably occurs through 
activation of the classical complement pathway. Evidence for 
activation of the classical complement pathway by SSRBC is 
two-fold. Firstly, both EDTA and EGTA, chelators of calcium 
ions, blocked the hemolytic activity against SSRBC. These 
chelators inhibit the mammalian classical pathway (3, 10). 
Secondly, carrageenan, which precipitates the first component 
of the classical complement pathway (1), depleted hemolytic 
activity against SSRBC, but not HRBC. The results of 
carrageenan treatment of turkey serum also suggest that 
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lysis of HRBC does not occur through the classical pathway. 
Zymosan and inulin activate the alternative complement 
pathway of mammals (3, 10, 15). In this study, depletion of 
hemolytic activity against both SSRBC and HRBC was observed 
after zymosan and inulin treatments. This would suggest 
depletion of a component(s) common to both complement 
pathways, for example components of the terminal membrane 
attack complex. The terminal complement pathway in avian 
species has not been characterized. Zymosan and inulin 
treatments of turkey serum suggest that a common complement 
pathway arises from the classical and alternative pathways, 
as similarly described for the mammalian system (11). 
Appl·ication of assays utilized in the study of mammalian 
complement has facilitated characterization of complement 
activity in turkeys. The present study shows convincing 
evidence that turkey complement may be activated through two 
pathways, these being the analogues of the mammalian 
classical and alternative complement pathways. Lysis of 
SSRBC occurs through an antibody-dependent pathway, which 
requires calcium and magnesium ions for efficient 
functioning. In contrast, the pathway effecting lysis of 
HRBC is antibody-independent and requires only magnesium ions 
for efficient functioning. Hence, hemolytic activity against 
SSRBC and HRBC, respectively, represents the classical and 
alternative complement pathways of turkeys. 
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SECTION II. ISOLATION AND CHARACTERIZATION OF THE THIRD 
COMPONENT OF TURKEY COMPLEMENT 
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ABSTRACT 
The third component (CJ) of complement was isolated and 
characterized from turkey plasma. 
chains joined by disulfide bonds. 
Turkey CJ consists of two 
The molecular weights of 
the a and~chains of turkey CJ are 120,000 and 75,000 
daltons, respectively. By crossed-immunoelectrophoresis, 
turkey CJ was identified to change in electrophoretic 
mobility after complement activation by inulin treatment of 
turkey serum. A monospecific antiserum to turkey CJ caused 
agglutination of sheep red blood cells sensitized with 
antibody and complement proteins, but did not cause 
agglutination of sheep red blood cells sensitized with 
antibody alone. Based on its structural similarity to CJ of 
other mammalian and avian species, its distinct 
electrophoretic mobility in complement-activated serum and 
its association with antibody-coated erythrocytes, the 
isolated turkey serum protein is identified as the third 
component of turkey complement. 
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rNTRODUCTrON 
The complement system consists of a group of serum 
proteins which have a significant role in defense against 
infectious agents, in particular, gram-negative bacteria 
(6, 15). Complement-mediated defense may occur through 
activation of either the classical or alternative pathways 
(14, 16). A critical step in the complement sequence is the 
cleavage and activation of the third component (C3) of 
complement. Both the classical and alternative complement 
pathways converge with the cleavage of C3, releasing a small 
fragment (C3a) with anaphylatoxic activity and a large 
fragment (C3b) which can bind covalently to target cell 
surfaces or immunoglobulins (1, 9, 10). The activated 
molecule, C3b may serve as an acceptor for additional 
complement components during the assembly of the membrane 
attack complex (20), or it may act as an opsonin recognized 
by macrophages or polymorphonuclear cells (6, 11). The 
significance of C3 in host resistance is exemplified by the 
occurrence of severe recurrent bacterial infections in humans 
with C3 deficiency (5). 
The third component of complement is the most abundant 
in human serum (1.2-1.3 mg/ml) (11). Human C3 is 
characterized as a glycoprotein (195,000 daltons) composed of 
two chains joined by disulfide bonds (3). Under reducing 
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conditions, the molecular weights are 127,000 and 75,000 
daltons for C3a and C3µ, respectively. Analogues of human C3 
have been identified and characterized in the chicken and 
quail (7, 8). These proteins are structurally similar to 
human C3, and have molecular weights of 190,000 and 184,000 
daltons for chicken C3 and quail C3, respectively. In 
addition to structural similarities to human C3, the avian 
analogues may possess the same functional group involved in 
covalent binding of C3b to cell surfaces. Both chicken and 
quail C3 are sensitive to methylamine, suggesting that the 
reactive group is a thiolester bond as reported for human C3 
( 19) • 
Research in turkey complement is limited to analysis of 
functional activity by various assays described for the 
measurement of human and mammalian complement (2, 17, 18). 
None of the individual turkey complement components have been 
identified or characterized. In the present study, we 
describe the first isolation of a turkey complement protein, 
which is analogous to the third component of human 
complement. 
63 
MATERIALS AND METHODS 
Experimental design. The first part of this experiment 
was a two step procedure which involved the production of a 
rabbit anti-turkey C3 antiserum. A suspension of zymosan 
with bound turkey complement proteins was used as the initial 
antigen to produce an antiserum reacting with several of the 
turkey complement proteins. The antiserum which resulted 
from this procedure and is subsequently ref erred to as an 
anti-turkey complement antiserum was then used in a 
modification of the crossed-immunoelectrophoresis procedure 
to precipitate a turkey serum protein, identified as C3. The 
precipitated rabbit antibody/turkey C3 complex was removed 
from the agarose, and used to immunize rabbits for production 
of .the anti-turkey C3 antiserum. To confirm that the rabbit 
antiserum reacted with a complement protein (C3), the 
antiserum was tested for its ability to hemagglutinate sheep 
red blood cells sensitized with antibody (EA) or sheep red 
blood cells sensitized with antibody and complement (EAC) • 
The anti-turkey C3 antiserum was then used in the second 
part of this experiment to examine sequential steps in the 
isolation of turkey C3 from plasma. Fractions collected 
during the isolation procedure were utilized in 
immunoelectrophoresis and analyzed with the anti-turkey C3 
antiserum. 
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·Turkey serum and plasma. Blood was collected from 
normal adult turkeys and allowed to clot at room temperature 
for 1 hour and at 4°c for 1 hour. Serum was harvested by 
centrifugation (1500 rpm, 20 minutes), pooled and stored in 
10 ml aliquots at -7o0 c ·until required. For turkey plasma, 
blood was collected in heparinized tubes and immediately 
centrifuged. Plasma was pooled and stored in 30 ml aliquots 
at -7o0 c until required. 
Complement-activated turkey serum was produced by 
treatment with inulin. Turkey serum was mixed with inulin 
(from Chicory root, SIGMA) at a ratio of one ml of serum to 
20 mg of inulin, and then incubated at 37°c for 30 minutes. 
Treated serum was centrifuged, diluted 1:8 and analyzed by 
crossed-immunoelectrophoresis. 
Production of rabbit antiserum to complement proteins. 
The initial antiserum to turkey complement proteins was 
produced by a procedure previously described for isolation of 
quail CJ (7). Briefly, 100 mg zymosan (SIGMA), an activator 
of the mammalian alternative complement pathway was incubated 
with 20 ml of turkey serum at 37°c for 1 hour. The serum-
treated zymosan was collected by centrifugation (2000 rpm, 
15 minutes), washed three times in phosphate-buffered saline, 
pH 7.2 (PBS) and then resuspended in PBS to one-half the 
original serum volume. Two rabbits were each injected 
intradermally with three doses (10 mg/dose) mixed with equal 
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volumes of Freund's adjuvant, at 10 day intervals. Rabbit 
sera were collected 10 days after the last immunization and 
immunoglobulins were purified by ammonium sulfate 
precipitation (50% saturation). 
Production of rabbit anti-turkey C3 antiserum. A 
modification of the crossed-immunoelectrophoresis procedure 
was used to isolate a precipitation band formed by the rabbit 
anti-turkey complement antiserum and normal turkey serum. 
The procedure involved removing some of the contaminating 
precipitation bands in the second-dimension agarose by 
incorporating a rabbit anti-turkey immunoglobulin antiserum1 
at a 20% final concentration in the first-dimension agarose. 
The isolated precipitation band observed in the second-
dimension agarose was cut from the gel, and used as an 
antigen to immunize rabbits. Rabbit immunizations were 
similar to those previously described. 
Purification of turkey C3. The initial purification 
step of turkey C3 was similar to that described for isolation 
of rabbit C3 (4) . Turkey plasma (300 ml) was taken to final 
concentrations of 10 mM ethylenediamine tetraacetic acid 
(EDTA) and 6.4 mM benzamidine-HCl. Turkey plasma was 
1The anti-turkey immunoglobulin antiserum was produced 
in our lab by immunizing rabbits with a preparation of turkey 
serum IgG (Hand L chains). 
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equilibrated with 4% (w/v) polyethlyene glycol (P4000, SIGMA) 
for 1 hour at 4°c, and then centrifuged (2500 rpm, 
30 minutes) . The supernatant was collected, and the 
precipitation repeated, taking the sample to 12% (w/v) 
polyethylene glycol. The precipitated proteins were 
collected by centrifugation and dialyzed against a 
0.01 M Tris-HCl buffer containing 0.03 M NaCl, 6.4 mM EDTA, 
and 6 mM benzamidine-HCl, pH 8.0. Twenty milliliters of the 
dialyzed sample were applied to a DEAE-cellulose column 
(Whatman-52, 2 x 20 cm) equilibrated with the same buffer. A 
stepwise elution of the plasma proteins was performed using 
the same buffer system and increasing NaCl molarities 
(0.05 M, 0.1 M, 0.15 M, 0.2 M, and 0.3 M). The protein 
fraction eluting with 0.05 M NaCl, was concentrated by 
ultrafiltration and applied to a sephadex G-200 column 
(3 x 90 cm). Contaminating turkey immunoglobulin was removed 
from the C3 sample by affinity chromatography using the 
rabbit anti-turkey immunoglobulin antiserum linked to 
cyanogen bromide activated-sepharose 4B (SIGMA). 
Immunoelectrophoresis and crossed-immunoelectrophoresis. 
Electrophoresis of samples was performed in 1% agarose in a 
tris-tricine buffer (0.024 M tricine, 0.062 M tris-HCl, 
0.003 M sodium azide, 0.003 M calcium lactate, pH 8.6). For 
immunoelectrophoresis, antigen samples were added to the wells 
(10 ul/well) and electrophoresed at 6 volts/cm for 2 hours. 
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Troughs were removed, and 150 ul of appropriate antibody were 
added to each trough. Samples were allowed to diffuse for 24 
hours, and then gels were washed in PBS to remove non-
precipitating proteins. For crossed-immunoelectrophoresis, 
10 ul of turkey serum (diluted 1:8) were added to each well, 
and electrophoresed in the first dimension agarose at 6 
volts/cm for 4 hours. Second-dimension electrophoresis was 
carried out at 2 volts/cm for 18 hours. Rabbit antibodies 
were incorporated into the second-dimension agarose at 20% 
final concentrations. Agarose gels from both procedures were 
washed in PBS for 24 hours, and then stained for protein using 
coomassie blue R250. 
Polyacrylamide gel electrophoresis (PAGE). Protein 
samples were analyzed by discontinuous PAGE in the presence of 
l%_sodium dodecyl sulfate. Non-reduced samples were analyzed 
in 7% polyacrylamide slab gels, and samples reduced with 2% 
~-mercaptoethanol were analyzed in gradient slab gels of 5 to 
15% polyacrylamide. Electrophoresis was carried out at 25 
mAmps, constant current for 4 hours. Gels were stained for 
protein with Coomassie-blue R250. 
Erythrocyte-Antibody and Erythrocyte-Antibody-complement 
production. Sheep red blood cells sensitized with specific 
antibody (EA) were prepared by mixing 5 ml of a 5% SRBC 
suspension with 10 ml of gelatin-veronal-buffered saline 
containing 10 mM EDTA, 1:200 turkey anti-SRBC antibody and 
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1:16 normal turkey plasma. Sheep red blood cells sensitized 
with specific antibody and complement proteins (EAC) were 
prepared similarly, except that the EDTA was removed to allow 
complement activation. Red blood cell suspensions were 
incubated at J7°c for 1 hour, and then centrifuged (1000 rpm, 
15 minutes). Red blood cells (EA and EAC) were resuspended 
to 2% final concentrations with PBS for use in the 
hemagglutination assay. 
Hemagglutination Assay. Two-fold dilutions of rabbit 
antisera (50 ul/well) were prepared in a microtiter test 
plate. Fifty microliters of red blood cell suspension (EA or 
EAC) were added to the serum dilutions, samples shaken and 
then allowed to settle for 2 hours. The hemagglutinating 
titer was recorded as the last serum dilution causing 
agglutination of the red blood cells. The rabbit antisera 
were tested in duplicate for each red blood cell suspension. 
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RESULTS 
The initial rabbit antiserum which was produced against 
serum-treated zymosan was found to react with several turkey 
serum proteins as demonstrated by crossed-
immunoelectrophoresis in Figure 1-1 . Two distinct 
precipitation bands were formed by proteins which 
predominated in the gamma-globulin fraction of turkey serum. 
one of these bands was observed to change in electrophoretic 
mobility (movement toward the anode) after activation of 
turkey complement by inulin treatment (data not shown). This 
precipitation band assumed to be C3, was selectively isolated 
by incorporating a rabbit anti-turkey immunoglobulin 
antiserum into the first-dimension agarose of the crossed-
immunoelectrophoresis procedure. The isolated precipitation 
bands resulting from normal turkey serum and inulin-treated 
turkey serum are shown in Figures 1-llA and 1-llB, 
respectively. By cutting the isolated precipitation band 
from the agarose and immunizing rabbits, a monospecific 
antiserum was subsequently produced which reacted with a 
protein in normal turkey serum, as shown in Figure 1-lllA. 
This turkey serum protein was observed to change in 
electrophoretic mobility after treatment of turkey serum with 
inulin, as shown in Figure 1-lllB. 
The monospecific antiserum, subsequently referred to as 
a putative anti-turkey C3 antiserum was tested for its 
Figure 1-1. 
Figure 1-11. 
Figure 1-111. 
Identification of turkey serum proteins by 
crossed-immunoelectrophoresis which react 
with the anti-turkey complement antiserum 
Adsorption of contaminating turkey serum 
proteins from normal turkey serum (A) and 
inulin-treated turkey serum (B) by 
incorporation of an anti-turkey 
immunoglobulin antiserum in the first-
dimension agarose of the crossed-
immunoelectrophoresis procedure 
Identification of turkey C3 by crossed 
immunoelectrophoresis in normal turkey serum 
(A) and inulin-treated turkey serum (B), 
using the anti-turkey C3 antiserum 
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hemagglutinating characteristics. The anti-turkey CJ 
antiserum hemagglutinated sheep red blood cells sensitized 
with turkey immunoglobulin and complement (EAC) with a titer 
of 1:J2. In contrast, the anti-turkey CJ antiserum did not 
hemagglutinate sheep red blood cells sensitized with turkey 
immunoglobulin (EA). 
Purified turkey CJ was obtained following a four-step 
isolation procedure. Turkey plasma was fractionated by 
precipitating proteins between 4 and 12% (w/v) polyethylene 
glycol. This sample of turkey serum proteins reacted with 
the anti-turkey CJ antiserum in immunoelectrophoresis (data 
not shown). The second step for CJ isolation was anion 
exchange chromatography using DEAE-cellulose. The elution 
profile of the proteins from the DEAE-cellulose column is 
shown in Figure 2. The protein fraction which eluted with 
0.05 M NaCl (shaded area) was found to contain the putative 
turkey CJ, as determined by immunoelectrophoresis (data not 
shown). In the third step, high and low molecular weight 
protein contaminants were removed by gel filtration using 
Sephadex G-200. At this point, the sample containing turkey 
CJ was also found to contain turkey immunoglobulin. The 
contaminating turkey immunoglobulin was adsorbed from turkey 
CJ by affinity chromatography. The various protein fractions 
obtained during the isolation procedures, as well as the 
putative turkey CJ sample are shown in Figure J. 
Figure 2. Elution profile of turkey plasma proteins from 
the DEAE-cellulose column, using increasing salt 
concentration. Arrows indicate changes in NaCl 
molarities starting with 0.03 M, and proceeding 
with 0.05 M, 0.1 M, 0.15 M, 0.2 M and 0.3 M. The 
fraction eluting with 0.05 M (shaded) was found 
to contain turkey C3 
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Figure J. Analysis of fractions obtained during isolation 
of turkey CJ by SOS-PAGE (5 to 15% acrylamide 
gel). samples were solubilized in buffer con-
taining 0.1% SOS and 2% mercaptoethanol, and 
boiled at 100°c for J minutes. Lanes represent 
molecular weight markers (MW), proteins precipi-
tated by polyethylene glycol (4 to 12% W/V) (A), 
proteins eluted with 0.05 M NaCl from OEAE-cellu-
lose column (B), proteins eluted from Sephadex G-
200 column (C), and purified turkey CJ (0). 
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Treatment of turkey C3 with p-mercaptoethanol reveals 
that it consists of two polypeptide chains, as shown in 
Figure 3. Examination of these chains in a 5 to 15% 
polyacrylamide gradient gel indicates molecular weights of 
120,000 and 75,000 for C3a and C3fi, respectively. 
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DISCUSSION 
In the present study, the third component of turkey 
complement was identified and isolated using var.ious 
immunological and biochemical techniques. Utilization of 
zymosan, a suspension of yeast cell walls to activate turkey 
complement facilitated the production of a rabbit antiserum 
to turkey complement proteins. Zymosan activation of 
complement has been used for the isolation of both mouse C3 
and quail CJ (7, 12). The antisera produced against the 
complement-bound zymosan in these previous reports were found 
to react primarily with the third component of complement of 
each of the respective species. The results of this study 
suggest that the rabbit anti-zymosan/turkey complement 
antiserum reacts with several turkey serum proteins, although 
two distinct precipitation bands were formed by proteins in 
the gamma-globulin fraction of serum. One of these proteins 
was observed to have a characteristic mobility in complement-
activated serum, as similarly described for the third 
component of other animal species (7, 8, 12). The second 
serum protein was precipitated by an anti-turkey 
immunoglobulin antiserum in the first-dimension agarose of 
the crossed-immunoelectrophoresis procedure, suggesting that 
this protein was turkey immunoglobulin. Further evidence 
indicating that the second protein was immunoglobulin is 
shown by its predominance in normal turkey serum. 
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To maintain the isolated turkey CJ as an active 
molecule, it was essential to add EDTA to turkey serum, as 
well as to subsequent buffers to prevent complement 
activation. In addition, benzamidine-HCl was included in 
buffers to prevent spontaneous activation of the purified 
product isolated from its serum inhibitors (J). Failure to 
use these inhibitors during CJ isolation resulted in high 
molecular weight complexes believed to be covalently-bound 
turkey IgG-CJ complexes (9). During isolation of CJ, turkey 
immunoglobulin was a common contaminant of the isolated CJ, 
as similarly described for human CJ isolation (J). For 
purification of human CJ, a procedure was developed in which 
contaminating proteins in the CJ sample.were removed by 
affinity chromatography (lJ). This procedure was 
successfully used for removing the contaminating turkey 
immunoglobulin, requiring two to three adsorptions for 
complete removal of the immunoglobulins. 
The purified turkey CJ obtained by the procedures 
outlined in this study was structured similarly to the third 
component of humans, chickens and quail (J, 7, 8). The 
isolated turkey protein is composed of two chains with 
molecular weights of 120,000 and 75,000 daltons, 
respectively. The third component of complement from humans, 
chickens and quail is composed of two chains linked by 
disulfide bonds. In these species, the larger chain has a 
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molecular weight range of 110,000 to 127,000 daltons, whereas 
the smaller chain has a molecular weight range of 68,000 to 
75,000. Hence, we have identified the isolated turkey serum 
protein as C3 based on its molecular similarity to C3 of 
other species, its characteristic mobility in complement-
activated serum, and its association with antibody-coated 
erythrocytes. 
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SECTION III. SERUM RESISTANCE AND VIRULENCE IN 
ESCHERICHIA COLI ISOLATED FROM TURKEYS 
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ABSTRACT 
Twenty-five strains of Escherichia coli isolated from 
turkeys were characterized for their serum resistance and 
virulence. An in vitro bactericidal assay was used to 
determine the serum resistance of E. coli. Virulence was 
determined by survival time following intravenous inoculation 
of each strain into 3-week old turkeys. Serum-resistant 
E. coli were generally found to be virulent for turkeys, 
whereas serum-sensitive E. coli were avirulent. Of the 25 
strains, 18 strains were placed in the two categories of 
serum-resistant/virulent and serum-sensitive/avirulent. 
Five strains were serum-resistant and avirulent and two 
strains were serum-sensitive and virulent. Serum resistance 
appears to be an important determinant of virulence for 
E. coli in turkeys. However, the requirement for other 
virulence factors, in addition to serum resistance, is 
suggested by the finding that 5 serum-resistant strains were 
avirulent in turkeys. 
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INTRODUCTION 
Escherichia coli is an economically important bacterial 
pathogen of broiler chickens and young turkeys. In turkeys, 
E. coli infection is most commonly characterized by subacute 
fibrinopurulent airsacculitis or acute septicemia (7) . The 
septicemic form of E. coli infection, colisepticemia, is 
often fatal; survivors may be unthrifty due to pericarditis, 
perihepatitis, airsacculitis and arthritis. The majority of 
E. coli infections of turkeys and broilers are caused by the 
serotypes 01, 02 and 078, but a large number of other 
serotypes have been isolated in a limited number of disease 
outbreaks (7, 11, 18). 
Some strains of E. coli resist clearance from the 
bloodstream by the liver and spleen, replicate to large 
numbers in blood, and cause death or severe lesions in 
infected turkeys (2). In contrast, E.coli strains which 
are avirulent for turkeys are readily cleared from the 
bloodstream and cause minimal lesions or disease. Few 
determinants of virulence have been characterized for E. coli 
isolated from poultry. Adherence of E. coli to the 
respiratory epithelium of turkeys may be important for 
initial infection (4, 15). Recently, virulence has been 
correlated with the efficient acquisition of iron from host 
tissues by some E. coli strains isolated from turkeys 
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(5). However, the molecular basis for survival of 
virulent E. coli strains in the bloodstream of turkeys 
remains largely unknown. 
The composition of the bacterial cell surface may 
influence the ability of bacteria to survive within the host 
tissues and body fluids. Components associated with the 
E. coli outer membrane are known to influence the activity of 
antibody, complement and phagocytes (22). Strains that 
cause bacteremia in humans commonly resist the bactericidal 
effects of serum (23), whereas enhanced virulence of 
serum-resistant E. coli for mice is largely attributable to 
inefficient opsonization by complement and resistance to 
phagocytosis (13). The objective of the present study was 
to determine the serum resistance and virulence of E. coli 
strains isolated from a variety of turkey tissues. 
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MATERIALS AND METHODS 
Bacteria. All strains of E. coli were isolated from 
turkey flocks in central Iowa by N. F. Cheville1 and 
H. J. Barnes2 • Twenty-five isolates were obtained from 
various tissues of turkeys including trachea, heart, liver 
and blood. Each isolate was confirmed as E. coli by standard 
bacteriological methods, and o, K, H serotypes were 
determined3 • The tissue source and serotype for each E. coli 
strain is given in Table 1. For the present study, each 
strain was streaked for purity on solid media and then grown 
18 hours in brain heart infusion (BHI) broth4 at 37°c. For 
each E. coli strain, a 3-week old turkey was inoculated 
intravenously with 0.1 ml of the broth culture, and a 0.1 ml 
blood sample was collected 2 hours later. Blood samples were 
.mixed with 10 ml of BHI broth and incubated overnight at 
37°c. Isolates from blood cultures were tested for purity, 
mixed with sterile glycerin (1:1, V/V), and stored at -8o 0 c 
as stock until required. Passage of the E. coli strains in 
vivo under standard conditions was done to ensure that 
1National Animal Disease center, Ames, IA. 
2North Carolina state University, Raleigh, NC. 
3 t" 1 . . Na iona Veterinary Services Laboratory, Ames, IA. 
4Difco Laboratories, Detroit, MI. 
88 
Table 1. The serotype and tissue source of E. coli isolates 
from turkeys 
Strain Serotypea Source 
1 078:K80:H9 liver 
2 Olab:K" :H7 liver 
3 02a:K-:NM liver 
4 036:K-:NM liver 
5 0143:K":H27 liver 
12 078:K80:H9 pericardium 
13 Oll:K" :H4 nasal sinus 
20 078:K" :H9 unknown 
26 036:K-:NM unknown 
27 078:K3:H9 heart blood 
28 078:K":NM trachea 
36 o·: K? :H4 trachea 
38 OX9 :K" :H4 liver 
39 02a:K2:NM liver 
40 02a:K2:H5 unknown 
42 Rough:K?:NM trachea 
43 078:K80:H9 unknown 
44 Oll:K" :H4 trachea 
48 08:K" :H4 trachea 
53 078:K":NM heart blood 
54 02a:K-:H5 liver 
66 078:K80:H9 pericardium 
68 078:K":H9 heart blood 
79 02a:K2:H5 liver 
80 088:K93:H8 liver 
aK. = K antigen present, but not identifiable with 
standard K antisera; K- = no K antigen present; K? = no tests 
made to determine the antigen; o· = o antigen present, but 
not identifiable with standard o antisera; NM = nonmotile. 
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differences observed in serum resistance and virulence were 
not due to effects of in vitro culture on expression of 
virulence factors. By examining strains of E. coli from a 
variety of turkey tissues, it was anticipated that a broad 
spectrum of virulence and serum resistance patterns would 
occur. 
Turkeys. Nicholas strain broad-breasted white turkeys 
(n=130) were obtained from a commercial hatchery1 and raised 
to three weeks of age in battery cages. Feed and water were 
supplied ad libitum. 
Serum. Pooled turkey serum was used as the source of 
complement. Blood was obtained from healthy, 4-week old 
turkeys and allowed to clot at room temperature for 1 hour 
and then at 4°c for 1 hour. Serum was separated by 
centrifugation, pooled, divided into 2 ml aliquots, and 
frozen at -7o0 c until required. Serum was tested for natural 
antibodies to all E. coli isolates by a microtiter 
agglutination assay (3). Two-fold serial dilutions of the 
serum were mixed with equal volumes of E. coli suspension 
(1 x 10 9 colony-forming units (CFU)/ml) in a microtiter test 
plate, and bacterial agglutination was recorded. The 
antibody titer of serum samples was recorded as the last 
dilution causing bacterial agglutination. 
1Midwest Turkey Hatchery, Dike, IA. 
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Bactericidal assay. The serum resistance of each 
E. coli strain was determined following the guidelines of 
Taylor (21). A 10 ul sample of a 24 hour BHI broth culture 
was used to inoculate 10 ml of sterile BHI broth prewarmed to 
37°c. The BHI broth subcultures were incubated for 2 hours 
at 37°c to produce bacteria in the logarithmic phase of 
growth. After incubation, the bacterial suspensions were 
centrifuged for 20 minutes at 3000 x g, and bacterial pellets 
were resuspended in 10 ml gelatin-veronal buffer (GVB++) 
containing 0.15 mM cac12 and 0.5 mM MgC1 2 , pH 7.4 (8). For 
the assay, reaction mixtures of 250 ul containing 25 ul of 
bacterial suspension (1 x 107 CFU/ml) and 225 ul of undiluted 
turkey serum were incubated at 37°c for 3 hours. Fifty 
microliter samples, collected initially and at the end of the 
three hour incubation, were placed in 9 ml GVB++. Numbers of 
viable bacteria were determined by plating 10-fold serial 
dilutions of these samples on blood agar plates. The 
bactericidal activity of turkey serum for each E. coli strain 
was determined in quadruplicate. 
Virulence assay. A 1:10 dilution (in phosphate-buffered 
saline, pH 7.4) of a 24 hour BHI broth culture of each 
E. coli strain was used as the inoculum (approximately 
2 x 108 CFU/ml). For each E.coli strain, five 3-week old 
turkeys were injected intravenously with 0.5 ml of the 
inoculum. Control birds were similarly injected with 0.5 ml 
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phosphate-buffered saline. Mortality was recorded 6, 12, 24, 
36, 48, 60, and 72 hours post-inoculation. Serum samples 
were collected from each turkey prior to challenge for 
determination of specific antibody against the E. coli strain 
used in the inoculum, as previously described. 
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RESULTS 
serum resistance of E. coli isolates. The turkey serum 
used to test serum resistance did not contain detectable 
antibody specific for the E. coli isolates, except for 
strains 3 and 44. With these two strains, the agglutinating 
antibody titer of the serum was 1:2. The strains of E. coli 
differed markedly in serum resistance as shown in Figure 1. 
Data are presented as the change in number of viable E. coli 
between the 3 hour and o hour samples, expressed as log10 
CFU/ml. Isolates of E. coli were classified as serum-
resistant when the number of viable E. coli in 3 hour samples 
was greater than in o hour samples. Isolates from the 
cardiac blood or pericardium were generally serum-resistant. 
In.contrast, strains isolated from the liver or trachea 
varied in their degree of serum resistance. All strains 
(n=9) with the 078 serotype were serum-resistant. The 
additional o-serotypes associated with serum resistance 
included 01, 0143, and 011 (one strain per serotype). 
Virulence of E. coli in turkeys. Antibodies specific 
for the E. coli challenge strains were not detectable in any 
of the poults before challenge (data not shown). The results 
of the E. coli challenge and comparison to serum resistance 
of each E. coli strain are presented in Figure 2. Virulence 
data are presented as the sum total in hours that poults 
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within a group survived after challenge, with the maximum 
survival time recorded as 360 hours (5 birds per group x 72 
hours) . For the purpose of comparison, an intermediate value 
of 180 hours was chosen to differentiate virulent and 
avirulent E. coli. However, virulence of E. coli strains 
varied greatly, ranging from death of all poults within 12 
hours for virulent strains to no deaths within 72 hours for 
avirulent strains. Strains with the 078 serotype were 
confirmed as highly virulent. Additional serotypes found to 
be virulent were 036 and 0143. Serum-resistant E. coli 
tended to be virulent (n=8), whereas serum-sensitive E. coli 
were avirulent (n=10). However, five strains were serum 
resistant but avirulent, and one serotype, 036:K-:NM was 
serum sensitive but highly virulent for turkeys. 
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nrscussroN 
rn a previous study, it was shown that virulent E. coli, 
when injected intravenously into turkeys multiplied in the 
blood and caused rapid mortality (7). Subsequently, it was 
found that virulent E. coli were able to resist clearance by 
the liver and spleen (2). The results of the present study 
indicate E. coli that are virulent for turkeys are likely to 
be serum-resistant. For example, all strains of the 078:K80 
serotype, which is commonly associated with colisepticemia, 
were serum-resistant. Virulent E. coli are often found in 
the blood and localized in certain tissues, including the 
pericardial sac (12). The ability to survive and multiply 
in these tissues requires several virulence factors, one of 
which is serum resistance. Isolation of virulent E. coli 
from liver would be expected in turkeys dying of 
colisepticemia, but avirulent strains could also colonize the 
liver post mortem by extension from the intestines. 
Therefore, depending on the circumstances of liver culture, 
either virulent or avirulent E. coli strains could be 
recovered. In contrast, culture of blood is likely to yield 
virulent E. coli strains as found in this study. All serum-
sensitive/avirulent strains identified in the present study 
were originally isolated from tissues other than blood. 
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Bacterial virulence is suggested to be multifactorial 
(19). The ability to resist the bactericidal effects of 
serum is one example of a characteristic associated with 
virulent organisms, as evident in this study. At the same 
time, there are multiple host defense mechanisms which 
respond to pathogenic organisms. Although some strains of 
E. coli in this study were serum-resistant, they were also 
avirulent for turkeys. The specific bacterial and host 
mechanisms responsible for the serum-resistant/avirulent 
E. coli phenotype are not known. One possibility may be the 
limitation of iron, and possibly other nutrients during an 
infection. Because iron is essential for bacterial growth, 
the ability to sequester iron from host tissues influences 
the pathogenicity of bacteria (6). For turkeys, 
virulence of E. coli is markedly enhanced by addition of 
exogenous iron (5), suggesting the importance of iron 
limitation by the host. The aerobactin iron-chelation system 
has been shown to be present in virulent avian E. coli 
strains and absent from most avirulent strains (14). 
Although five avirulent strains of E. coli in this study were 
serum-resistant, they may have inadequate iron-chelation 
systems and hence, are unable to survive in the bloodstream 
of turkeys. An alternative explanation for the serum-
resistant/avirulent strains is based on interaction of the 
bacteria with humeral components and cells of the mononuclear 
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phagocytic system. The role for humeral factors, such as 
antibody and complement in enhancing bacterial clearance by 
the liver and spleen is well established. Hepatic clearance 
of virulent E. coli from the bloodstream of turkeys is 
markedly enhanced by passive immunization with specific 
antibody (1). In vivo decomplementation of squirrel 
monkeys and mice resulted in decreased clearance of E. coli 
from the blood (9, 20). The differences in virulence of 
serum-resistant E. coli may reflect variations in complement 
activation or deposition of opsonic complement fragments such 
as C3b onto the bacterial surface. The availability of 
surface-bound C3b on serum-resistant strains of E. coli may 
facilitate clearance by the liver and spleen in turkeys. 
The mechanisms for virulence associated with the serum-
sensitive serotype, 036:K-:NM are not understood. The 
response of the bacteria in vitro may not always reflect the 
events occurring in vivo due to the complexity of the host 
response. In the hostile in vivo environment, E. coli 
036:K-:NM may undergo phenotypic change from serum-sensitive 
to serum-resistant. Alterations in the bacterial surface 
composition can have a significant effect on serum resistance 
(16) . Hence, although serum-sensitive in vitro, the 
036:K-:NM E. coli serotype may express surface structures in 
vivo that result in resistance to the bactericidal effects of 
serum. This type of observation is not limited to E. coli in 
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turkeys. Salmonella cholerae-suis var kunzendorf (strain 38) 
has also been found to be serum-sensitive but virulent for 
mice (10). 
The importance of serum resistance as a determinant of 
virulence for E. coli in turkeys has been demonstrated in the 
present study. Restriction of iron by the host or deposition 
of opsonically active complement fragments on the bacterial 
surface may be important host defense mechanisms against 
serum-resistant E. coli strains. Serum resistance as a 
determinant of virulence for gram-negative bacteria has been 
suggested for Pasteurella multocida in turkeys and Salmonella 
cholerae-suis var kunzendorf in mice and pigs (10, 17). 
The significance of serum resistance in E. coli from turkeys 
is exemplified by strains of the 078:K80 serotype which is a 
prevalent cause of colisepticemia. 
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SECTION IV. INTERACTION OF TURKEY COMPLEMENT WITH 
ESCHERICHIA COLI ISOLATED FROM TURKEYS 
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ABSTRACT 
The bactericidal effects of turkey complement were 
determined using serum-sensitive and serum-resistant strains 
of Escherichia coli isolated from turkeys. Inactivation of 
turkey complement by heating (s6°c for 40 minutes) or by 
chelation with 10 mM ethylenediamine tetraacetic acid (EDTA) 
eliminated bactericidal activity. Serum-sensitive E. coli 
were killed by turkey serum treated with 10 mM ethylene 
glycol-bis (p -aminoethyl ether)-N,N,N',N'-tetraacetic acid 
(EGTA) and 5 mM magnesium chloride. Exposure of normal 
turkey serum to either serum-sensitive or serum-resistant 
E. coli resulted in equivalent reductions in hemolytic 
activity of the serum. Pretreatment of serum-resistant 
E •. coli with antibody rendered the bacteria sensitive to the 
bactericidal effects of normal turkey serum. These results 
indicate that serum-sensitive E. coli are readily killed by 
the alternative complement pathway, serum-sensitive and 
serum-resistant E. coli activate the complement system 
equally well, and antibody is required for complement-
mediated killing of certain serum-resistant strains of 
E. coli from turkeys. 
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INTRODUCTION 
Gram-negative bacterial strains which cause disseminated 
infections and bacteremia are usually found to be resistant 
to the bactericidal effects of serum. Such is the case with 
gonococcal infections and K-1 Escherichia coli infections in 
humans (24, 27). A similar situation exists with E. coli in 
poultry. Escherichia coli infection of poultry is often an 
extension from the respiratory tract, resulting in acute 
colisepticemia (5). In a previous study, virulent E. coli 
strains isolated from turkeys were usually found to be serum-
resistant, whereas avirulent strains were serum-sensitive 
(7). Therefore, serum resistance appears to be an important 
virulence determinant shared by several gram-negative 
bacterial pathogens across divergent host species. 
The bactericidal activity of serum against gram-negative 
bacteria is primarily mediated by antibody and complement 
(28, 32). The role of lysozyme is unclear, but it may have a 
minor role in bacteriolysis (19). The complement system 
consists of a group of serum proteins which function in the 
formation of a membrane attack complex (C5b-9) responsible 
for complement-mediated killing of certain bacterial strains 
(16, 29). In the absence of antibody, complement activation 
may proceed through the classical (6, 18) or alternative (25) 
pathways. Specific antibody not only facilitates classical 
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pathway activation, but may also be important in enhancement 
of C3b deposition by the alternative pathway, and 
stabilization of the terminal components of C5b-9 (11, 12). 
The virulence factors that allow certain strains of bacteria 
to resist the bactericidal effects of complement are not well 
understood. Bacterial surface structures which may be 
important for serum resistance include smooth 
lipopolysaccharide, acidic capsular polysaccharide and 
plasmid-determined outer-membrane proteins (2, 21, 30). The 
molecular basis for serum resistance centers on interaction 
of C5b-9 with the bacterial outer membrane. For example, 
current evidence suggests that serum resistance of the human 
pathogens, E. coli and Salmonella minnesota, is due to 
release of C5b-9 from the outer membrane of these bacteria 
(13-15). In contrast, stable insertion of C5b-9 into the 
outer membranes of their serum-sensitive counterparts results 
in complement-mediated killing. 
Little is known of the interaction of turkey complement 
with bacterial pathogens. The present study was conducted to 
determine the role of turkey complement in the killing of 
E. coli isolated from turkeys and to examine the interaction 
of antibody and complement with serum-resistant strains of 
E. coli. 
107 
MATERIALS AND METHODS 
Experimental Design. This study consisted of two parts, 
corresponding to each of the objectives. The first part 
examined the role of complement in the bactericidal activity 
of turkey serum for E. coli. Three strains of E. coli, 
described in Table 1 are known to be sensitive to turkey 
serum and were therefore used to analyze complement function. 
Turkey serum was depleted of complement activity by heat 
treatment, or by differential chelation of calcium and 
magnesium ions using ethylene diamine tetraacetic acid (EDTA) 
or ethylene glycol-bis- (3 aminoethyl ether-N,N,N' ,N'-
tetraacetic acid (EGTA). EDTA inhibits both the classical 
and alternative pathways of complement activation, whereas 
EGTA supplemented with magnesium ions inhibits only the 
classical pathway (8) . The ability of serum-sensitive 
E. coli to survive in treated sera was determined in 
triplicate using the bactericidal assay. 
The interaction of antibody and complement with serum-
resistant E. coli was examined in the second part of this 
study. Four strains of serum-resistant E. coli, described in 
Table 1 were individually mixed with turkey serum. Serum 
samples treated with the E. coli strains were then examined 
for residual complement activity using hemolytic assays. 
This procedure was used to determine whether inability to 
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TABLE 1. Serotype, serum resistance and virulence of E. coli 
strains isolated from turkeys 
strain serotype 
a serum resistance b . 1 c viru ence 
1 078:K80:H9 resistant virulent 
3 02a:K-:NM sensitive avirulent 
4 036:K-:NM sensitive virulent 
13 Oll:K" :H4 resistant avirulent 
20 078 :K" :H9 resistant avirulent 
39 02a:K2:NM sensitive avirulent 
53 078:K" :NM resistant virulent 
aK- = no K antigen present. K" = K antigen present, but 
not identifiable with standard K antisera. NM = nonmotile. 
bserum resistance was previously reported as the change 
between the 3 hour and o hour samples in the bactericidal 
assay, recorded as log10 CFU/ml (7). 
cVirulence was reported as the sum total of hours turkey 
poults (n=5) survived after an intravenous challenge with 
E.coli strains (7). 
activate complement was a mechanism for serum resistance of 
E. coli isolated from turkeys. In addition, two serum-
resistant strains of E. coli were sensitized with specific 
turkey antibody produced against each of the respective live 
bacteria to determine the influence of antibody on the 
bactericidal activity of turkey serum. Immune sera were 
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heat-inactivated and chelated with EDTA to prevent complement 
activation during the sensitization procedure. Therefore 
immune sera served only as sources of antibody. Because EDTA 
and turkey serum components other than antibody were present 
during sensitization of E. coli, EDTA, or EDTA and a normal 
heat-inactivated turkey serum were included as controls to 
ensure that the effects observed were due to the antibody and 
not other external factors. Escherichia coli strains 
sensitized with antibody were then tested for serum 
resistance in duplicate using the bactericidal assay. 
Bacteria and culture conditions. Escherichia coli 
strains, originally isolated from turkey flocks in central 
Iowa, were previously examined for serum resistance and 
virulence in turkeys (7). Each of the E. coli strains used 
in this study are representatives of the categories, serum-
resistant/virulent, serum-resistant/avirulent, serum-
sensitive/virulent or serum-sensitive/avirulent. The 
characteristics for each E. coli strain are shown in Table 1. 
To reduce effects of original isolation procedures and 
in vitro culture conditions, each bacterial strain was 
passaged in a three-week old turkey and reisolated from the 
bloodstream, as previously described (7) . Escherichia coli 
reisolated from blood were grown in brain heart infusion 
broth, mixed in glycerol (1:1, v/v), and stored at -7o0 c. 
Escherichia coli strains 3, 4, and 39 were used in part one 
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of this study to determine the role of complement in the 
bactericidal activity of turkey serum, and strains 1, 13, 20, 
and 53 were used in the second part of the study to identify 
mechanisms associated with serum resistance of E. coli 
isolated from turkeys. 
serum. Blood was obtained from healthy 4-week old 
turkeys and allowed to clot at room temperature for 1 hour 
and then at 4°c for 1 hour. Serum was harvested, pooled and 
frozen in aliquots at -10°c until required. Serum was tested 
for specific agglutinating antibodies to each of the E. coli 
strains using a microtiter agglutination assay (1). Two-fold 
dilutions of serum were mixed with equal volumes of bacterial 
suspension (1 x 109 colony-forming units (CFU)/ml) in a 
microtiter test plate. The antibody titer of serum was 
recorded as the last dilution causing agglutination of 
bacteria. 
For part one of this study, 5 ml aliquots of serum were 
either heat-inactivated (56°c, 40 minutes), treated with 
10 mM EDTA, or treated with 10 mM EGTA and 5 mM MgC1
2
. An 
additional 5 ml aliquot remained untreated and served as a 
positive control for indication of serum sensitivity of the 
E. coli strains. 
Bactericidal assay. The serum resistance of each 
E. coli strain was determined as previously described (7). 
Briefly, bacteria in the logarithmic phase of growth were 
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resuspended in 10 ml gelatin-veronal buffer (GVB++) 
containing o.15 mM cac12 and 0.5 mM MgC12 , pH 7.4 (9), 
yielding a bacterial suspension of approximately 1 x 10
7 
CFU/ml. For the assay, reaction mixtures of 250 ul 
containing 25 ul of bacterial suspension and 225 ul of 
undiluted turkey serum were incubated at 37°C for 3 hours. 
Fifty microliter samples collected initially, and at the end 
of the three hour incubation, were placed in 9 ml GVB++. 
Numbers of viable bacteria were determined by plating 10-fold 
serial dilutions of these samples on blood agar plates. 
Sensitization of E. coli with antibody. Immune sera 
against two serum-resistant strains of E. coli (strains 1 and 
53) were produced in turkeys. Four-week old turkeys were 
immunized with 106 live organisms, and subsequently boosted 
one week later with 108 organisms. serum was collected two 
weeks after the last immunization and the complement was 
heat-inactivated (56°c, 40 minutes). For sensitization, 
dilutions of immune sera were chosen that would not result in 
agglutination of the bacteria. Serum-resistant E. coli were 
resuspended in 9 ml of each of the following buffers: GVB++; 
GVB++ containing 10 mM EDTA; GVB++ containing 10 mM EDTA and 
an appropriate dilution of immune sera (ITS); and GVB++ 
containing 10 mM EDTA and the same dilution of heat-
inactivated normal turkey serum (NTS) • Bacterial suspensions 
were incubated for 30 minutes at 37°c, centrifuged and 
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bacterial pellets resuspended in 10 ml GVB++ (approximately 
io7 CFU/ml). A one milliliter sample of each bacterial 
suspension was serially diluted ten-fold, and dilutions were 
plated on blood agar plates for bacterial counts. The effect 
of sensitization of E. coli with specific antibody was then 
determined using the bactericidal assay. 
Residual complement activity. A block titration was 
performed using a serum-sensitive strain of E. coli (strain 
3) to determine a concentration of bacteria, as well as serum 
that yielded minimum residual hemolytic complement activity. 
These concentrations of bacteria and serum were used to study 
complement activation by serum-resistant E. coli (strains 1 1 
13, 20 and 53). Final reaction mixtures were 1 ml containing 
0.1 ml bacteria (10 9 CFU/ml) and 0.9 ml of 70% turkey serum. 
Samples were incubated for 1 hour at 37°c, centrifuged and 
supernatants were collected for measurement of residual 
hemolytic complement activity. Bacteria were tested in 
duplicate. 
Hemolytic complement assays. Sheep red blood cells 
(SRBC) sensitized with turkey anti-SRBC antibody (5 x io 8 
cells/ml) were prepared as previously described (9) for the 
measurement of total complement activity. Horse red blood 
8 cells (2.5 x 10 cells/ml) were prepared for measurement of 
complement activity by the alternative pathway (20). Two-
fold dilutions of serum were mixed with equal volumes of red 
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blood cells with a final volume of 1.0 ml. Suspensions were 
incubated at 37°c for 1 hour for sensitized SRBC and 2 hours 
for HRBC, as previously described (20). The hemolytic 
complement titer was spectrophotometrically determined and 
recorded as the reciprocal of the dilution yielding 50% 
hemolysis of red blood cells (9). 
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RESULTS 
Role of complement in the bactericidal activity of 
turkey serum. Undiluted normal turkey serum was bactericidal 
for E. coli strains 3, 4, and 39, as shown in Figure 1. The 
level of bactericidal activity of serum varied with the 
strain, with strain 4 being highly susceptible to serum, and 
strains 3 and 39 being intermediate in serum sensitivity. 
This bactericidal activity was not attributed to antibody, as 
serum was negative for agglutinating antibodies (data not 
shown). Treatment of serum by heating to S6°C for 40 minutes 
resulted in a loss of bactericidal activity against all three 
E. coli strains. Chelation of calcium and magnesium ions 
from turkey serum by EDTA inhibited bactericidal activity 
against strains 4 and 39, but not against strain 3. Each 
E. coli strain remained serum-sensitive in turkey serum 
treated with EGTA and Mgcl2 • 
Effects of antibody on serum-resistant E. coli. strains 
1 and 53 were resistant to the bactericidal effects of turkey 
serum in the absence of antibody, indicated in Figure 2. 
Sensitization of the bacteria with antibody did not affect 
bacterial numbers (data not shown). In contrast, both 
strains when sensitized with antibody were highly susceptible 
to the bactericidal effects of turkey serum. Bacterial 
numbers decreased by two logarithmic units during the three 
hour incubation when serum-resistant E. coli were sensitized 
Figure 1. Role of complement in the bactericidal activity 
of turkey serum. Normal turkey serum (NTS), 
heat--inactivated turkey serum (HITS), serum 
treated with 10 mM EDTA, and serum treated with 
10 mM EGTA and 5 mM MgCl 2 were examined for 
bactericidal activity against E. coli. Shown is 
the mean log10 CFU/ml change between the 3 and o 
hour samples in the bactericidal assay plus the 
standard deviation of triplicate samples 
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Figure 2. Effect of antibody to serum-resistant E. coli. 
strains of serum-resistant E. coli were pre-
treated with GVB++, GVB++ containing 10 mM EDTA, 
GVB++ containing 10 mM EDTA and heat-inactivated 
normal turkey serum (NTS), or GVB++ containing 
10 mM EDTA and heat-inactivated immune serum 
(ITS). Values represent the mean log10 CFU/ml 
change between the 3 and o hour samples in the 
bactericidal assay plus the standard deviation of 
duplicate samples 
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with specific antibody. The presence of EDTA or other serum 
components during sensitization with antibody did not 
markedly affect the serum resistance of strains 1 and 53. 
However, with strain 1, there was a log10 CFU/ml difference 
between incubation in GVB++ and incubation in normal heat-
inacti vated turkey serum chelated with EDTA. 
Residual hemolytic complement activity. Treatment of 
serum with either serum-sensitive or serum-resistant E. coli 
caused a decrease in hemolytic activity, as indicated in 
Table 2. Lysis of both sensitized sheep red blood cells and horse 
red blood cells was decreased by treatment of serum with 
strains 1, 13, and 20. In contrast, treatment of serum with 
strain 53 did not affect the lysis of sensitized sheep red 
blood cells, but did affect hemolytic activity against horse 
red.blood cells. Virulent/serum-resistant strains 1 and 53 or 
avirulent/serum-resistant strains 13 and 20 did not differ in 
ability to deplete serum complement. However, the 
virulent/serum-resistant strain 53 only affected the hemolytic 
activity against horse red blood cells. 
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Table 2. Hemolytic complement activity of turkey serum 
treated with various E. coli strains 
Residual complement activity 
E. coli strain SSRBC HRBC 
control 14.8 10.5 
3 6.1 5.4 
1 4.4 4.2 
53 13.2 5.1 
13 5.8 6.6 
20 5.9 5.4 
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DISCUSSION 
In the present study, the bactericidal activity of 
turkey serum for E. coli was found to be the result of 
complement activation. Inactivation of complement by heat 
treatment or by chelation of calcium and magnesium ions using 
EDTA abolished the bactericidal activity of serum against 
E. coli. This would suggest that complement may have an 
important role in infection. Antibody-independent killing by 
complement may proceed through the classical (18, 31) or 
alternative (22, 25) pathways. In this study, the 
alternative pathway which is expressed in EGTA-chelated serum 
had a predominant role in the killing of serum-sensitive 
strains of E. coli. The alternative complement pathway is 
reported to have a significant role in the host against 
several types of infectious agents (25, 26, 3). Activation 
of the alternative complement pathway in the absence of 
antibody provides the host with an early non-specific defense 
mechanism. 
In contrast, some strains of gram-negative bacteria may 
require specific antibody for complement-mediated killing 
(23, 11, 27). In the present study, this is indicated by the 
observation that E. coli strains usually resistant to the 
bactericidal effects of turkey serum were killed when 
sensitized with specific antibody. The specificity of this 
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antibody is not known. Previous-work suggests that 
antibodies specific for bacterial lipopolysaccharide, outer 
membrane proteins or capsular polysaccharide facilitate 
complement-mediated killing (4, 23). 
Treatment of serum with EDTA failed to completely 
abolish bactericidal activity, and with strain 3, bacteria 
were killed by the chelated serum. EDTA is reported to have 
a negative effect on the growth of bacteria and their ability 
to resist serum (6, 17). For example, EDTA has a 
bactericidal effect on rough bacterial strains and a 
bacteriostatic effect on smooth forms (6). The effect 
produced by EDTA is attributed to release of 
lipopolysaccharide and hence, alteration in the bacterial 
cell wall (10). The results of the present study confirm 
previous reports, and suggest that EDTA may influence 
survivability and growth of E. coli in turkey serum. This 
observation only holds true for serum-sensitive E. coli. In 
this study, serum-resistant E. coli strains were not affected 
by EDTA treatment. Therefore, different mechanisms may exist 
between serum-resistant and serum-sensitive E. coli in their 
ability to resist the effects of EDTA, and subsequently grow 
in serum. The differences between these strains may reflect 
variations in sequestering the divalent cations from EDTA for 
bacterial growth. Alternatively, if EDTA treatment releases 
lipopolysaccharide as previously described, then factors 
123 
other than the presence of lipopolysaccharide on the surface 
of E. coli may be necessary for serum resistance. 
The mechanisms for serum resistance of E. coli isolated 
from turkeys are not associated with an inability to activate 
serum complement. The four serum-resistant E. coli strains 
examined in this study were found to activate and consume 
turkey complement equally as well as a serum-sensitive 
strain. Complement activation by the serum-resistant strains 
primarily occurred through the alternative pathway, as 
indicated by the reduction in hemolytic activity against 
horse red blood cells. Hence, serum resistance appears to be 
determined at the level of the individual complement 
components and their interaction with the bacterial surface. 
studies of E. coli and s. minnesota and their interaction 
with human complement suggest that serum resistance is 
determined by the instability of the membrane attack complex 
(C5b-9) in the bacterial outer membrane (13-15). Release of 
the membrane attack complex from the bacterial outer membrane 
was associated with the serum-resistant strains. study of 
the components of the membrane attack complex of turkey 
complement and their interaction with the outer membrane of 
E. coli may determine mechanisms for serum resistance of 
E. coli isolated from turkeys. 
In conclusion, many E. coli strains isolated from 
turkeys are readily killed by activation of the alternative 
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complement pathway. However, some strains of E. coli require 
the presence of antibody for complement-mediated killing. 
This is particularly true for strains that normally resist 
the bactericidal effects of turkey serum. Although serum-
resistant, E. coli strains 13 and 20 were previously found to 
be avirulent for turkeys (7). The host mechanisms causing 
avirulence of these strains are unclear. It may be that 
complement activation by these serum-resistant strains 
results in the stable deposition of opsonic complement 
fragments on the bacterial surface, with incomplete formation 
of the membrane attack complex. In contrast, virulent E. 
coli from turkeys may require mechanisms to resist both the 
bactericidal and opsonic effects of complement. 
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GENERAL SUMMARY AND DISCUSSION 
This research was conducted to obtain an understanding 
of turkey complement and its role in Escherichia coli 
infections of turkeys. The three major objectives were to: 
1. characterize the complement activity of turkeys 
2. isolate and characterize the third component of 
turkey complement 
3. clarify the role of complement in defense 
against E. coli infection in turkeys 
In humans and other selected mammals, activation of the 
complement system occurs through a classical or alternative 
pathway (22, 87). Avian complement has received little 
research emphasis; therefore, knowledge of individual avian 
complement components is limited. Because assays for 
detecting avian complement activity are limited, there 
existed some controversy as to whether avian species have a 
classical pathway (60, 61). In this research, two hemolytic 
assays were developed to measure distinct pathways of 
complement activation in turkey serum. The lysis of sheep 
red blood cells sensitized with specific turkey antibody 
identified a pathway in turkey serum which required antibody 
and the divalent cations, calcium and magnesium. This 
pathway is analogous to the human classical pathway. In 
contrast, lysis of horse red blood cells by turkey serum was 
antibody-independent and only required magnesium ions. 
lJO 
Heterologous erythrocytes are lysed in the absence of 
antibody by activation of the human alternative pathway 
(88, 96). Therefore, lysis of.horse red blood cells by 
turkey serum identified complement activity analogous to the 
alternative pathway in humans. Carrageenan, an inhibitor of 
mammalian classical activity (12), prevented lysis of the 
SSRBC, but not the lysis of HRBC. In contrast, zymosan and 
inulin, both of which activate the mammalian alternative 
complement pathway (28, 95), depleted complement activity 
against both SSRBC and HRBC. Treatment of turkey serum with 
activators of mammalian complement confirms the differences 
observed in the two hemolytic test systems and demonstrates 
that both classical and alternative complement activity are 
present in turkeys. 
Isolation of the third component of turkey complement 
was facilitated by the initial production of a putative 
rabbit anti-turkey CJ antiserum. Because there is an 
incompatibility between avian and mammalian. complement 
components (JS), and very few of the avian complement 
components are isolated, characterization of turkey CJ was 
based on structural and immunological techniques. 
The rabbit anti-turkey CJ antiserum agglutinated sheep 
red blood cells sensitized with antibody arid turkey 
complement, but did not agglutinate sheep red blood cells 
sensitized with antibody alone. Therefore the turkey protein 
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reacting with the anti-turkey C3 antiserum was a complement 
protein. In humans, mice, chickens and quail, C3 has a 
characteristic electrophoretic mobility in complement-
activated serum (56, 59, 77, 117). The anti-turkey C3 
antiserum reacted with a turkey protein which moved toward 
the anode after complement activation by inulin, as similarly 
described for the third component of the previously mentioned 
species. Hence, a possible C3 molecule of turkey complement 
was identifiable by the crossed-immunoelectrophoresis 
procedure. 
The protein identified as turkey C3 was similar in 
structure to C3 of humans, chickens and quail. It was 
composed of two chains (120,000 and 75,000 molecular weights) 
joined by disulfide bonds. The reactive functional group of 
turkey C3 was not identified. However, it was found that 
turkey serum was sensitive to methylamine, suggesting that 
the active group in turkey C3 was a thiolester bond, 
similarly described for human C3 (116). 
An alternative means for isolation of turkey C3 would be 
to use the rabbit anti-turkey C3 antiserum in affinity 
chromatography. However, there was a tendency for turkey 
immunoglobulin to predominate the sample eluted from the 
affinity column. The reason for this is unclear. Although 
the antiserum reacts specifically with a complement protein 
identified by crossed-immunoelectrophoresis, it binds turkey 
132 
immunoglobulin more efficiently in the affinity column. ~t 
may be that the rabbit antiserum reacts with an antigenic 
determinant found on turkey C3 and turkey immunoglobulin. 
The final objective of this research was to characterize 
the role of turkey complement in E. coli infections of 
turkeys. Turkey complement has a significant role in the 
bactericidal activity of serum, as similarly described for 
human complement (118, 121). In the absence of antibody, 
activation of the alternative pathway of turkey complement 
can lead to killing of E. coli strains isolated from turkeys. 
However, antibody-dependent complement killing was required 
for some E. coli strains. The requirement for antibody to 
render these E. coli strains sensitive to complement-mediated 
killing may enable the bacteria to replicate in the blood and 
tissues during the pre-antibody phase of infection. For 
example, two E. coli strains, normally serum-resistant and 
virulent for turkeys were readily killed by turkey serum when 
sensitized with specific antibody. 
The results from this research suggest that virulent 
E. coli isolated from turkeys are more likely to resist the 
bactericidal effects of serum mediated by complement. In 
contrast, avirulent E. coli strains are usually serum-
sensitive. Hence, serum resistance can be considered an 
important virulence factor for E. coli in turkeys. However, 
some E. coli strains require other virulence factors, in 
lJJ 
addition to serum resistance for survival in turkeys. 
Although serum-resistant, five E. coli strains were avirulent 
for turkeys. In a previous report, efficient acquisition of 
iron from host tissues was necessary for virulence of E. coli 
in turkeys (9). The iron acquisition mechanisms of the 
E. coli strains used in this study were not characterized. 
It is speculated that the serum-resistant/avirulent E. coli 
strains identified in this research may lack efficient iron 
acquisition mechanisms or other essential virulence factors. 
Alternatively, the presence of opsonic complement fragments 
on the surface of these serum-resistant E. coli may lead to 
opsonophagocytosis of the bacteria, and hence avirulence. 
For example, some bacterial strains which are usually 
virulent are readily cleared by hepatic phagocytes when 
opsonized by antibody or complement (2, 44). 
Although this research has provided an understanding of 
turkey complement and has identified a role for turkey 
complement in E. coli infections, several areas remain 
unclear. Is there a common terminal pathway of complement 
activation in turkey serum? Zymosan and inulin treatments of 
turkey serum suggest that there is a common complement 
pathway. Does turkey CJ have the same functional group - a 
thiolester bond - as that of human CJ? What are the host and 
bacterial mechanisms responsible for avirulence of serum-
resistant E. coli? What virulence factors are associated 
1J4 
with the serum-sensitive/virulent E. coli strains? Why do 
some strains of E. coli resist the bactericidal effects of 
complement? Utilization of purified complement components 
has facilitated analysis of human complement-bacterial 
interactions. Unfortunately, few avian complement components 
have been isolated. Purified turkey CJ and an anti-turkey CJ 
antibody can be used to clarify the role of CJb as an opsonin 
in host defense mechanisms of turkeys to serum-resistant 
E. coli. 
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